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ABSTRACT 
Cancer metastasis is a frequent manifestation of malignant melanoma progression.  
Successful invasion into distant organs by tumor cells must include attachment to microvessel 
endothelial cells, and degradation of extracellular matrix.  Heparan sulfate proteoglycans are 
ubiquitous macromolecules associated with cell surface and extracellular matrix of a wide range 
of cells and tissues.  Heparanase is an extracellular matrix degradative enzyme which degrades 
the heparan sulfate chains of heparan sulfate proteoglycans.  To investigate effects of changes in 
heparanase gene expression in metastatic melanoma cells, we constructed adenoviral vectors 
containing the full-length human heparanase cDNA in both sense (Ad-S/hep) and anti-sense 
orientations (Ad-AS/hep).  We demonstrated increased heparanase expression and activity in 
melanoma cell lines following Ad-S/hep infection by Western blot analyses and heparanase 
activity assay.  Conversely, heparanase content was significantly inhibited following infection 
with Ad-AS/hep.  Alteration of heparanase protein expression by these adenoviral constructs 
correlated with invasive cellular properties in vitro and in vivo.  Unexpectedly, overexpression of 
heparanase inhibited brain tumor formation in vivo possibly by extensive remodeling of the 
extracellular matrix which in turn modifies growth factor signaling and activity.   
Finally, cell-surface heparan sulfate is also known to inhibit or promote tumorigenesis 
depending on size and composition.  We proposed that heparanase generates bioactive heparan 
sulfate chains from the melanoma cell-surface that modify biological activities associated with 
vascular endothelial growth factor, a molecule essential for brain metastasis.  Heparanase-
degraded melanoma cell-surface heparan sulfate stimulated migration, but not proliferation of 
melanoma in vitro.  It also enhanced angiogenesis in vivo, independent of vascular endothelial 
growth factor activity, an unexpected finding.  Interestingly, melanoma cell-surface heparan 
 xi
sulfate did not have an observed effect on endothelioma migration in vitro.  We also attempted to 
characterize the melanoma cell-surface heparan sulfate isolated by heparanase degradation by 
ion-pair high pressure liquid chromatography.  This method proved to be not sensitive enough to 
detect nanogram quantities of HSGAG present in our samples. 
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CHAPTER I 
INTRODUCTION 
STATEMENT OF PROBLEM AND HYPOTHESIS 
Cancer is the second leading cause of death in the United States, and is a major health 
concern in the population worldwide [Cancer Facts and Figures, American Cancer Society 
(2006)].  Cancer metastasis is the spread of tumor cells from a primary site of origin to distant 
organs and it accounts for 90% of cancer related mortalities.  The brain is a frequent site of 
metastasis from various primary tumors including malignant melanoma (Graf, Buchberger et al. 
1988).  Malignant melanoma has had the highest increase in incidence in the US over the last 
three decades, especially among young adults, and is the primary cause of skin cancer related 
mortalities owing to metastasis (Bogenrieder and Herlyn 2003). 
Although metastatic mechanisms are not completely identified, it has been demonstrated 
that metastasis is not a random event.  In stead, it is the result of a complex series of events that 
occurs between normal cells, tissues, endothelial cells and malignant cells (Nakajima, Irimura et 
al. 1988; Bogenrieder and Herlyn 2003).  In order to metastasize, cells must first detach from the 
primary tumor, enter the vasculature, circulate through the blood, attach to a vessel wall, exit the 
vasculature, and establish themselves in new surroundings producing primary metastasis. This 
whole process may then be repeated to give rise to secondary metastasis (Nicolson 1982; Fidler 
2003). The processes of intravasation or extravasation requires degradation of basement 
membranes, extracellular matrices (ECM), and connective tissue mediated by proteolytic 
enzymes such as heparanase (HPSE), matrix metalloproteases (MMPs), and/or aspartic, cysteine, 
and serine proteases (Nakajima, Irimura et al. 1988; Joyce, Freeman et al. 2005). 
Heparan sulfate proteoglycans (HSPG) are one of the main components of the cell-
surface and ECM.  These are macromolecules composed of a core protein with heparan sulfate 
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chains (HS) covalently attached to it.  HSPG are ubiquitous in the eukaryotic system. Substantial 
evidence accumulated over the last three decades indicates that HSPG act to inhibit invasion by 
promoting tight cell-cell and cell-ECM interactions (Bernfield, Gotte et al. 1999; Iozzo 2001; 
Sanderson 2001).  Degradation of HS chains weakens cell-cell and cell-matrix adhesion in 
melanoma and other tumor cells (Dhodapkar, Kelly et al. 1997; Ma and Geng 2000; Engbring, 
Hoffman et al. 2002).  HSPG also act both as reservoirs of growth factors and as co-receptors for 
ligand binding and subsequent intracellular signaling (Iozzo, Cohen et al. 1994; Vlodavsky and 
Friedmann 2001).  These heparin-binding factors are involved in growth, invasion, angiogenesis, 
and tumor progression ((Bernfield, Gotte et al. 1999; Iozzo 2001; Vlodavsky and Friedmann 
2001). 
HS degradative enzymes, such as heparitinases, heparinases from Flavobacterium 
heparinum, or endoglucosaminidases, cleave HS to di- and tetra-saccharides, which are too short 
for growth factor receptor and ECM ligand binding (Ernst, Langer et al. 1995; Ernst, 
Venkataraman et al. 1996; Liu, Shriver et al. 2002).  On the other hand, HPSE is an endo-β-D-
glucuronidase that cleaves HS at specific intrachain sites resulting in fragments of appreciable 
size (10-20 sugar units) (Nakajima, Irimura et al. 1984; Nakajima, Irimura et al. 1988; Marchetti 
1997; Vlodavsky and Friedmann 2001).  HPSE has been recently cloned as the only mammalian 
HS-degrading enzyme (Hulett, Freeman et al. 1999; Kussie, Hulmes et al. 1999; Toyoshima and 
Nakajima 1999; Vlodavsky, Friedmann et al. 1999).  HPSE degrades HS chains of HSPG on the 
cell surface and ECM of a wide range of normal and neoplastic tissues (Rapraeger 1995; Iozzo 
1998; Bernfield, Gotte et al. 1999; Iozzo 2001; Sanderson 2001).  Degradation of HSPG by 
HPSE weakens the cell-matrix barrier and releases growth factors and cytokines bound to HS 
which can then initiate signaling events necessary for tumor progression (Sanderson, Yang et al. 
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2004; Sanderson 2005).  Increased HPSE expression has been associated with increased growth, 
metastasis, and angiogenesis of tumors (Vlodavsky and Friedmann 2001).  This suggests the 
notion that by remodeling HSPG, HPSE releases HS-bound angiogenic/growth factors and 
modulates growth factor activities in metastasis (Marchetti, Denkins et al. 2003; Reiland, 
Sanderson et al. 2004).  We proposed to test the hypotheses 1) whether altering HPSE protein 
expression will alter metastatic phenotype of melanoma and 2) whether HPSE supports 
tumorigenesis by releasing bio-active HS from the melanoma cell-surface. 
STATEMENT OF RESEARCH OBJECTIVES 
The overall goal of this project was to investigate the importance of HPSE and HPSE-
degraded HS chains as critical regulators of melanoma tumorigenesis.  The specific aims of this 
research were as follows: 
I. Modulate hpse gene expression in melanoma by an adenoviral gene delivery method 
to upregulate or downregulate its expression and determine the following biological 
effects in vitro and in vivo: 
1. Establish if hpse gene expression could be increased or decreased by adenoviral 
vectors carrying the gene in sense and anti-sense orientations, respectively and 
determine if HPSE protein expression and activity is modified accordingly. 
2. Determine if altered HPSE expression enhances or inhibits invasion and 
metastasis in vitro and in vivo, respectively. 
II. Determine if HPSE-degraded melanoma cell-surface HS act as promoters of vascular 
endothelial growth factor (VEGF)-mediated activity in melanoma: 
1. Determine if HPSE-degraded cell surface HS modifies VEGF-mediated 
melanoma migration and proliferation. 
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2. Determine if HPSE-degraded cell surface HS modifies VEGF-mediated 
angiogenesis in vivo. 
3. Characterize the HPSE-degraded cell surface HS products. 
On the whole, the results obtained from this research indicate the following: HPSE 
expression and activity can be modified to alter the metastatic phenotype of melanoma; and, 
HPSE-degraded melanoma cell-surface HS are bio-active and augment cell migration and 
angiogenesis independent of VEGF in melanoma.  The research is presented in a manuscript 
format in individual chapters with an appropriate title for the fundamental theme of each chapter. 
Chapter II: Antisense-Mediated Suppression of Heparanase Gene Inhibits Melanoma Cell 
Invasion 
Chapter III: Overexpression of Heparanase Inhibits Brain-Metastasis In Vivo  
Chapter IV: Heparanase-Degraded Cell-Surface Heparan Sulfate Promotes Melanoma Cell 
Migration and Angiogenesis  
LITERATURE REVIEW 
Cancer Metastasis: The “Seed and Soil” Hypothesis 
Cancer metastasis accounts for 90% of cancer-related deaths and is the second leading 
cause of death in the United States.  Understanding the metastatic process at the systemic, 
cellular, and molecular levels is essential in cancer research (Bogenrieder and Herlyn 2003; 
Marchetti, Denkins et al. 2003).  Researchers have been studying the process of cancer 
metastasis for more than 100 years now, and are slowly beginning to understand the mechanisms 
by which metastatic cells arise from the primary tumors or the site of origin, as well as why 
certain tumor types have a propensity to metastasize to specific organs. 
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In 1889, an English surgeon, Stephen Paget, proposed that metastasis depends on cross-
talk between selected cancer cells that he termed as the ‘seed’s and specific organ 
microenvironments that he termed as the ‘soil’.  His idea that metastasis is a non-random process 
still holds forth today (Paget 1889).  Paget noticed the discrepancy in the relative blood supply 
and the frequency of metastases in selected organs.  He analyzed more than 900 autopsy records 
of patients with various primary tumors. His study indicated a non-random pattern of metastasis 
to visceral organs and bones.  To Paget, these findings suggested that the occurrences of 
metastasis were not due to chance, as was the popular perspective of that time, but that certain 
tumor cells or the ‘seed’s have distinct affinity for certain host organs or the ‘soil’. His 
conclusions were that the seed and soil had to be compatible in order to give rise to metastases 
(Paget 1889). 
In 1929, James Ewing confronted Paget’s ‘seed and soil’ theory, and suggested that 
metastases result simply due to mechanical factors such as the anatomical configuration of the 
vascular system (Ewing 1928).  This theory was accepted till the 1970s, when the selective 
nature of metastasis was documented by Hart and Fidler (Hart and Fidler 1980; Hart, Talmadge 
et al. 1981).  Analysis of experimental metastasis in syngeneic mice established that mechanical 
arrest of tumor cells in the capillary bed of remote organs was definitely important, but 
subsequent proliferation and growth leading to secondary lesions were indeed influenced by the 
specific organ environment (Hart and Fidler 1980).  Further clinical data analyses on site 
preferences of metastases from different human malignancies suggested that regional metastatic 
involvement could be explained by anatomical or mechanical considerations.  For example, 
efferent venous circulation or lymphatic drainage leads to metastasis formation in regional lymph 
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nodes, but metastases to distant organs from various types of primary tumors were indeed site 
specific (Sugarbaker 1979; Weiss 2000). 
In 1989, during a symposium honoring the centennial anniversary of Paget’s ‘seed and 
soil’ hypothesis, George Poste commented, “There are few scientists, historical or contemporary, 
whose work will withstand 100 years of scrutiny and not succumb to the depressing trend of 
modern publications — to ignore papers published more than five years ago”.  Finally, both 
Paget’s and Ewing’s hypotheses proved to be correct and overlapping to some extent to this date.  
In essence, in order for a tumor cell to metastasize, its interactions with the host homeostatic 
factors are essential to promote tumor cell growth, survival, angiogenesis, invasion and 
metastasis. 
Cancer metastasis is a well-organized process (Fig. 1.1) (Nicolson 1982; Fidler 2003; 
Marchetti, Denkins et al. 2003); namely, benign neoplasms undergo a series of sequential but 
distinct changes to reach a malignant state.  For example, a tumor can initially be benign and 
then become malignant through acquisition of mutations before proceeding all the way through 
the metastatic cascade.  The mutations acquired lead to abnormal and uncontrolled proliferation.  
Once the tumor reaches the size of 1-2 mm, it needs vascular support (angiogenesis), to maintain 
tumor viability (Folkman 1986).  In order to metastasize, cells must first detach from the primary 
tumor, enter the vasculature or intravasate, circulate through the blood, attach to vessel walls, 
exit the vasculature or extravasate, and establish in a new surrounding, producing primary 
metastasis.  This whole process is then repeated to give rise to secondary metastasis (Fig. 1.1) 
(Nicolson 1982; Fidler 2003).  The steps of angiogenesis, arrest and adhesion, and intravasation 
or extravasation involve subtle to extensive cell-surface degradation and remodeling of the ECM 
by various proteolytic enzymes secreted by the tumor cells (Liotta 1986). 
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Figure 1.1. The steps of metastasis.  A.  Cellular transformation and tumor growth. Growth of 
neoplastic cells for expanding tumor mass is initially supplied by simple diffusion from the 
surrounding tissue.  B.  Angiogenesis must occur once a tumor mass dimension exceeds 1–2 mm. 
in diameter.  The synthesis and secretion of angiogenic factors launch a capillary network from 
the surrounding host tissue.  C.  Local invasion of the host stroma by some tumor cells that have 
detached themselves from the primary tumor by several parallel mechanisms to enter the 
circulation.  Thin-walled venules and lymphatic channels that proffer very little resistance to 
penetration by tumor cells are often the most common route for intravasation.  D.  On entering 
the circulation, most tumor cells die.  A few surviving tumor cells travel through the vasculature 
and subsequently become trapped in the capillary beds of distant organs by sticking either to 
capillary endothelial cells or to subendothelial basement membrane.  E.  Extravasation occurs 
consequently by mechanisms similar to those of invasion.  F.  Adherence and proliferation in the 
distant organ parenchyma completes the primary metastatic process.  The steps are then repeated 
by the tumor cells to produce additional/secondary metastases [reproduced with permission from 
Marchetti, D., Denkins, Y. et al. (2003), "Brain-metastatic melanoma: a neurotrophic 
perspective." Pathol Oncol Res 9(3): 147-58]. 
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Metastatic Melanoma 
Malignant melanoma has the highest increase in incidence over the past three decades in 
the US population, and is the primary cause of skin cancer-related mortalities due to metastasis 
[Cancer Facts and Figures, American Cancer Society (2006)].  Based on clinical and 
histopathological features, melanoma progression occurs in five steps (Fig. 1.2) (Clark, Elder et 
al. 1984; Meier, Satyamoorthy et al. 1998): 1) common acquired and congenital nevi with 
structurally normal melanocytes, 2) dysplastic nevus with structural and architectural atypia, 3) 
early radial growth phase (RGP) primary melanoma, 4) advanced vertical growth phase (VGP) 
primary melanoma with competence for metastasis, and 5) metastatic melanoma.  Progression 
from a resting melanocyte to a common acquired nevus occurs frequently and does not involve 
genetic abnormality.  However, it is proposed that melanocytes progress to a nevus by escaping 
the keratinocyte surveillance (Valyi-Nagy, Hirka et al. 1993).  Keratinocytes control growth, 
morphology, and antigenic phenotype of melanocytes by establishing direct contact through the 
cell-cell adhesion receptor E-cadherin (Valyi-Nagy, Hirka et al. 1993).  E-cadherin expression is 
reduced early in the nevus stage and is lost in the majority of melanomas whereas N-cadherin is 
upregulated in nevi and melanomas; this shift in cadherin profile changes cellular adhesive 
properties and promotes communication with N-cadherin-expressing fibroblasts and endothelial 
cells while keratinocytes lose control (Hsu, Wheelock et al. 1996; Meier, Satyamoorthy et al. 
1998).   
Progression from dysplasia to RGP primary melanoma happens spontaneously without 
additional molecular changes; however, switch from RGP to metastasis competent VGP is 
biologically and clinically complicated (Satyamoorthy, DeJesus et al. 1997; Meier, 
Satyamoorthy et al. 1998).  Additionally, VGP cells have growth characteristics comparable to  
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Figure 1.2.  Maturation, differentiation, transformation and progression of melanocytic 
tumors.  The role of melanoblasts in melanogenesis remains unknown.  Melanoma develops and 
progresses stepwise from nevic lesions; progression from normal melanocyte to nevus could be 
initiated by loss of keratinocyte control or contact between melanocytes and keratinocytes due to 
loss of E-cadherin expression and upregulation in N-cadherin expression (blue arrow).  Genetic 
changes that allow transition from commonly acquired (benign) nevus to dysplastic nevus/RGP 
melanoma are yet to be identified.  Additional genetic changes promote the progression from 
RGP melanoma to VGP along with expression of adhesion molecules like αvβ3, ICAM (red 
arrow).  At the VGP (tumorigenic) step, increased growth, invasion and stromal proteolysis 
finally lead to metastasis (adapted from Clark, Elder et al. 1984; Meier, Satyamoorthy et al. 
1998).  
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metastatic cells including anchorage-independent growth in soft agar and tumor formation in 
immunodeficient mice (Kath, Jambrosic et al. 1991).  VGP primary melanomas also exhibit 
cytogenetic abnormalities, suggesting genomic instability, and they can achieve metastatic 
phenotype through selection in growth factor-free medium or by induction of invasion in vitro 
through artificial basement membranes.  This suggests that alterations in cell–matrix and cell–
cell signaling are critical for progression to the metastatic phenotype (Fig. 1.2) (Kath, Jambrosic 
et al. 1991; Meier, Satyamoorthy et al. 1998). 
About 40%-60% of melanoma cases fatally metastasize to the brain (Isaiah, Gabriele et 
al. 1999; Bogenrieder and Herlyn 2003).  The brain is a unique organ confined within the skull 
and is surrounded by the blood brain barrier (BBB). The BBB acts as a selective diffusion barrier 
at the level of the cerebral microvascular endothelium and is characterized by the presence of 
tight cell-cell junctions and a lack of fenestrations in the capillaries (Fenstermacher, Gross et al. 
1988; Uwe and Hartwig 2000).  Therefore, the brain metastatic tumor cells first have to breach 
the BBB in order to invade into the brain tissue.  Metastases to most parts of the body are silent 
and hence generally well-tolerated and unnoticed initially, but due to its confined nature, brain 
tumor formation is usually symptomatic and results in rapid deterioration in health  (Menter, 
Herrmann et al. 1994).  The symptoms are characteristically due to cerebral edema which is 
further aggravated by the lack of a lymphatic circulation in the brain.  The resulting deregulation 
of homeostasis leads to impaired normal brain function and warrants treatment which is often 
difficult but necessary (Sawaya, Ligon et al. 1996; Soffietti, Ruda et al. 2002).   
The rising incidence of melanoma and the high rate of brain metastasis alone would be 
adequate grounds for alarm, but together they make the area of brain-metastatic melanoma a 
particularly challenging biological and clinical problem (Nicolson, Menter et al. 1996).  
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Therefore, melanoma is one of the best studied solid tumors with respect to tumor invasion and 
metastatic spread in humans (Hofmann, Houben et al. 2005).  In view of the fact that the 
mechanisms for melanoma metastasis to the brain are not yet fully understood, it is extremely 
important to gain better insights into the molecular mechanisms responsible in order to devise 
successful treatment strategies.  The various steps of metastasis involve cell-surface remodeling 
and degradation of the ECM by proteolytic enzymes, an important tumor-host interaction in the 
metastatic cascade (Liotta 1986).  The ECM, HSPG, and HPSE are critical in this aspect of 
tumorigenesis (Bernfield, Gotte et al. 1999; Iozzo 2001; Sanderson 2001; Vlodavsky and 
Friedmann 2001; Sasisekharan, Shriver et al. 2002; Sanderson, Yang et al. 2004; Sanderson 
2005).  
Extracellular Matrix 
The extracellular matrix (ECM) is a fibrillar meshwork of a variety of proteins and 
polysaccharides secreted by the cells.  The major components of the ECM are the structural 
proteins collagens and elastin; cell adhesive or anti-adhesive proteins such as laminin, 
fibronectin, vitronectin, and tenascin; the proteoglycans that have a complex protein core with 
even more diverse glycosaminoglycan (GAG) side-chains attached to them; and the soluble 
signaling molecules such as growth factors, cytokines, and chemokines that are bound to the 
ECM by the heparan sulfate glycosaminoglycans (HSGAG) (Lin and Bissell 1993; Lin and 
Perrimon 2000).  The ECM not only provides a physical barrier between cells and tissues and 
supports tissues with mechanical strength and elastic properties, it also acts as a scaffold for 
different cellular functions including cell growth, migration, differentiation and survival (Taipale 
and Keski-Oja 1997).  Development of a multicellular organism from a single cell involves an 
enormous amount of complexity and cell-cell and cell-ECM communication between different 
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cells, and organ systems.  The ECM provides a structural basis for multicellularity, whereas 
soluble and insoluble hormones and growth factors transfer the information required for 
construction of complex cellular structures (Taipale and Keski-Oja 1997).  Interaction of ECM 
molecules with each other or with their specific receptors on the cell surface activated by ligand 
binding leads to rearrangement of the cytoskeletal network. This, in turn, stimulates signal 
transduction cascades leading to alterations in gene expression and subsequent biological activity 
(Lin and Perrimon 2000; Xinhua and Norbert 2002).  
Synthesis of ECM is highly regulated by the cells whereby modification and processing 
of signals occurs at the cell surface leading to altered cell function in response to stimuli 
(Sasisekharan and Venkataraman 2000).  The ECM is remodeled during development and under 
pathological conditions such as wound healing and cancer (Timpl and Brown 1996).  ECM-
remodeling enzymes are therefore likely to affect cell and tissue function and are tightly 
regulated by the cells under normal physiological conditions.  However, in a cancerous state, 
these enzymes are deregulated (Liotta 1986, Stetler-Stevenson, Aznavoorian et al. 1993; Werb 
1997).  While intensive research has been done on enzymes capable of degrading and 
remodeling the protein components in the ECM (e.g. matrix metalloproteases, aspartic, cysteine, 
and serine proteases) (Stetler-Stevenson, Aznavoorian et al. 1993; Werb 1997), limited attention 
was paid to glycosidase HPSE that modifies the HSGAG on the HSPG where the melanoma 
metastasis occur (Sanderson, Yang et al. 2004; Sanderson 2005). 
Heparan Sulfate Proteoglycans: Structure and Function 
The proteoglycan component of the ECM has received much attention in the 
development of cancer metastasis, as it is present both in the ECM and at the cell surface, and is 
directly implicated in the cell-tissue interface (Sanderson, Yang et al. 2004; Sanderson 2005).  
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Proteoglycans play important roles in both how the cell processes signals that arise from the cell-
surface and the ECM, and how a signaling molecule once released from the cell-surface, diffuses 
to a distant site and is processed there (Liu, Shriver et al. 2002).  Proteoglycans are a superfamily 
of glycoproteins that are distinguished by the covalent attachment of one or more GAG chains to 
the protein core.  Four classes of GAGs have been identified so far on the proteoglycans: heparan 
sulfate (HS)/heparin, chondroitin sulfate (CS), dermatan sulfate (DS), and keratan sulfate (KS) 
(Kjellen and Lindahl 1991).  The proteoglycans of interest are usually HSPG since all eukaryotic 
cells express HSPG at their cell surface.  Genetic mutants that disrupt HSPG core protein 
synthesis and modification demonstrated that HSPG core protein regulates the interaction of cells 
with extracellular ligands during development (Kramer and Yost 2003). 
Two families of polypeptides are known to carry the majority of the cell surface HS on 
mammalian cells, the syndecans and the glypicans, while perlecan resides in the ECM (Fig. 1.3) 
(Blackhall, Merry et al. 2001).  The four members of the syndecan family (syndecans 1-4) are 
transmembrane proteins expressed on nearly all cell types through development and adulthood.  
Syndecan expression can be deregulated under certain pathophysiological conditions, including 
the processes of tumor onset, progression and metastasis (Sanderson 2001).  The six members of 
the glypican family (glypicans 1-6) are cell-surface HSPG attached to the plasma membrane via 
glycosylphosphatidylinositol (GPI) anchors.  Glypicans are localized in the rafts and caveolae, 
and may be involved in caveolar uptake of different biomolecules and viruses resulting in 
selective regulation of cytokine and growth factor signaling (Fransson, Belting et al. 2004).  
Perlecan, the major HSPG in the ECM, are important in cell adhesion, proliferation, 
differentiation, glomerular filtration, and during development through modification of growth 
factor binding and signaling (Jiang and Couchman 2003; Hacker, Nybakken et al. 2005).  
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Figure 1.3. Mammalian HSPG.  Syndecan 1–4 are encoded by separate genes. These are 
transmembrane proteins with short cytoplasmic tails with 3-5 HS (Red) are attached near the N-
terminus in the ecotodomain. Syndecan 1, 2 and 4 also bear CS (Blue) side chains near the cell 
surface. The syndecan core proteins are least conserved in the ectodomains even though the HS 
attachment sites are highly homologous.  Six glypican core proteins (Gpc1–6) are encoded by 6 
different genes, their extracellular globular glycoprotein cores attach to the cell membrane by a 
glycosylphosphatidylinositol (GPI) anchor with 2-3 HS chains positioned close to the cell 
surface.  The ECM-resident perlecan consists of a large multidomain core protein (400 kDa) to 
which several HS chains attach near the terminal globule (adapted from Blackhall, Merry et al. 
2001). 
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During tumorigenesis, these ECM and cell-surface HSPG are remodeled along with the 
rest of the ECM by various matrix-degrading enzymes including endoglycosidases, matrix 
metalloproteases, aspartic, cysteine, and serine proteases to facilitate tumor cell proliferation, 
angiogenesis, invasion, and metastasis (Joyce, Freeman et al. 2005).  HSPG promote tumor 
progression by releasing their HS-bound growth factors and cyto/chemokines that are now 
capable to signal through their cognate receptors, combined with alterations in the BM/ECM, 
that facilitate angiogenesis and tumor invasion by enzymatic action of HPSE (Fig. 1.4) 
(Sanderson 2001; Sanderson, Yang et al. 2004; Joyce, Freeman et al. 2005; Sanderson 2005). 
Heparan Sulfate Glycosaminoglycans: Structure and Function 
HSGAG are ubiquitously expressed on the surface of all eukaryotic cells and are 
important regulators of normal and pathological physiology (Sasisekharan, Shriver et al. 2002).  
HSGAG are synthesized in the Golgi apparatus starting with four monosaccharides linked to a 
serine-glycine repeats flanked by hydrophobic and acidic domains on the core protein.  The 
typical linear polysaccharide is then synthesized by the sequential addition of a glucosamine 
linked to an uronic acid with many possible disaccharide unit combinations (Gallagher 2001).  
These different combinations are based on the fact that O-sulfation can occur at the 2-O position 
of uronic acid and at the 6-O and 3-O positions of the glucosamine.  This creates eight different 
arrangements because each site can be either sulfated or unsubstituted plus the possibility for 
sixteen additional different combinations of disaccharides resulting from the uronic acid 
component being either iduronic acid or glucuronic acid.  Finally, the N-position of the 
glucosamine can either be sulfated, acetylated, or unsubstituted, resulting in 48 varied 
possibilities for disaccharide structures (Fig. 1.5) (Esko and Lindahl 2001). 
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       HPSE          EC 
 
        
Tumor Cell 
Figure 1.4.  Model of endoglycosidase HPSE function within the tumor microenvironment.  
HPSE cleaves HS chains (Red) releasing growth factors bound to HS fragments.  HPSE activity 
on HS augments the biological activity of growth factors with resulting stimulation of cell 
proliferation (Kato, Wang et al. 1998; Liu, Shriver et al. 2002).  Growth factors released by 
HPSE can act on both tumor cells and endothelial cells (EC) (adapted from Sanderson, Yang et 
al. 2004). 
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Figure 1.5.  Disaccharide sequences present in heparan sulfate.  A glucosamine is alternately 
linked to a uronic acid (either glucuronic acid or iduronic acid) with many possible disaccharide 
unit combinations (Gallagher 2001).  HS predominantly contain glucuronic acid over iduronic 
acid.  The different combinations are based on the fact that O-sulfation can occur at the 2-O 
position of uronic acid and at the 6-O and 3-O positions of the glucosamine.  This creates eight 
different arrangements because each site can be either sulfated or unsubstituted leading to the 
prospect for sixteen additional different combinations of disaccharides by the fact that there are 
two possibilities for the uronic acid component which can be either iduronic acid or glucuronic 
acid. Finally, the N-position of the glucosamine can be sulfated, acetylated, or unsubstituted, 
resulting in 48 varied possibilities for disaccharide structures (R = –H or –SO3, X = -Ac or –SO3, 
Y = –OH or –OSO3, Z = –OH or –OSO3). 
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The immense structural diversity of HSGAG allows them to bind and interact with 
numerous proteins including growth factors, chemokines, morphogens, and enzymes.  Growth 
factors including basic fibroblast growth factor (bFGF), vascular endothelial growth factor 
(VEGF), platelet-derived growth factor (PDGF), and, insulin-like growth factor are known to be 
important for tumor development (Nurcombe, Smart et al. 2000; Iozzo 2001; Sasaki, Higashi et 
al. 2004).  The specificity of growth factor binding and interactions is dependent on the HSGAG 
sequence including sulfation pattern, spacing of binding sites, and the three-dimensional 
structure of the HSGAG chain (Rapraeger 1995; Sasisekharan, Shriver et al. 2002; Robinson, 
Mulloy et al. 2006).  HSGAG present on tumor cells also contain bioactive sequences that may 
affect tumor-cell phenotype in relation to cell growth and metastasis (Liu, Shriver et al. 2002; 
Sasisekharan, Shriver et al. 2002).  The expression pattern and the structural integrity of HSGAG 
on the cell surface may change with the metastatic transformation of certain cell types; e.g., B16 
melanoma cells with high metastatic propensities have a lower concentration of cell surface 
HSGAG than sublines with less metastatic potential (Kure, Yoshie et al. 1987).  Highly 
metastatic B16 sublines also degrade HSGAG faster than sublines of lower metastatic spread 
(Nakajima, Irimura et al. 1983).   
HSGAG are directly involved with the angiogenic process by acting as co-receptors with 
angiogenic growth factors (Iozzo 2001).  As the interface between tumor cells and normal host 
cells, HSGAG mediate tumor and host cell interactions (Raman, Venkataraman et al. 2003).  
HSGAG can also influence tumor metastasis to sites such as the brain by mediating interactions 
between cancer cells, platelets, endothelial cells, and host organ cells (Varki and Varki 2002).  
When intact, HSGAG prevent metastasis by acting as a physical barrier in the ECM.  HPSE 
secreted by tumor cells degrades HSGAG on the cell-surface and ECM to increase the 
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invasiveness of tumor cells both by breaching the physical barrier as well as by releasing the HS-
bound growth factors that aid in the metastatic process (Vlodavsky and Friedmann 2001; 
Sanderson 2005). 
Heparanase in Health and Disease 
Discovery 
Heparanase or HPSE is an endo-β-D-glucuronidase that cleaves HS side chains at a 
limited number of intra-chain sites yielding HS fragments of 5–7 kDa (Fig. 1.6) (Freeman and 
Parish 1998; Pikas, Li et al. 1998; Vlodavsky and Goldshmidt 2001).  HPSE activity was first 
identified in rat liver tissue (Hook, Wasteson et al. 1975).  Later it was found that HPSE activity 
correlated with increased lung metastatic potential in B16 sublines (Nakajima, Irimura et al. 
1983), and in aggressive lymphoma (Vlodavsky, Fuks et al. 1983).  Since then, HPSE activity 
has been linked to a wide number of primary and metastatic cancers including cancers of the 
bladder, colon, stomach, breast, pancreas, brain, and melanoma (Friedmann, Vlodavsky et al. 
2000; Gohji, Okamoto et al. 2001; Koliopanos, Friess et al. 2001; Marchetti and Nicolson 2001; 
Maxhimer, Quiros et al. 2002; Tang, Nakamura et al. 2002; Simizu, Ishida et al. 2004).  HPSE 
activity correlates with the metastatic potential of all tumor-derived cells studied so far, possibly 
due to enhanced cell dissemination resulting from HS cleavage and remodeling of the cell-
surface and the ECM (Parish, Freeman et al. 2001; Vlodavsky and Friedmann 2001).  Notably, 
HPSE activity has also been detected in platelets, endothelium, macrophages, astrocytes and 
placenta which implicates its role in normal physiological functions such as neovascularization, 
inflammation, autoimmunity, and embryonic implantation (Matzner, Vlodavsky et al. 1992; 
Marchetti, Li et al. 2000, Dempsey, Brunn et al. 2000; Parish, Freeman et al. 2001; Vlodavsky 
and Friedmann 2001; Revel, Helman et al. 2005).  The enzyme is preferentially expressed in the  
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Figure 1.6:  Glycosaminoglycan sequence recognized by endoglycosidase HPSE. The exact 
order of iduronic acid, glucosamine and glucuronic acid residues recognized by HPSE is yet to 
be determined.  Heparan sulfate with unsubstituted glucosamine residues is not cleaved by 
HPSE.  On the other hand, heparan sulfate with glucosamines modified by N-acetylation or N-
sulfation is susceptible to cleavage by HPSE.  Hexuronic acid carboxyl groups are required for 
substrate cleavage but are dispensable for recognition because carboxyl-reduced heparan sulfate 
is a potent inhibitor; O sulfation is not an absolute requirement for cleavage, provided that the 
glucosamine residue is N-substituted (Bai, Bame et al. 1997; Freeman and Parish 1998; Pikas, Li 
et al. 1998).  Enzymatic cleavage produces a glucuronic acid at the newly formed reducing 
terminus (marked by the arrow) [reproduced with permission from Dempsey, Brunn et al. 
(2000), “Heparanase, a potential regulator of cell-matrix interactions. Trends in Biochemical 
Sciences 25, 349-351”]. 
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cells of developing vascular and nervous systems during embryogenesis (Goldshmidt, Zcharia et 
al. 2001).  HPSE also promotes migration of endothelial cells and activated immune cells 
suggesting that HPSE has important roles in both pathologic and non-pathological conditions 
(Nakajima, Irimura et al. 1988; Matzner, Vlodavsky et al. 1992; Schubert, Ilan et al. 2004).   
HPSE activity was initially attributed to proteins with molecular weights varying from 8 
to 130 kDa, therefore raising the potential existence of several HS-degrading endoglycosidases 
(Dempsey, Brunn et al. 2000; Parish, Freeman et al. 2001; Vlodavsky and Friedmann 2001).  
However, cloning of a single human hpse cDNA sequence by several groups independently 
(Hulett, Freeman et al. 1999; Kussie, Hulmes et al. 1999; Toyoshima and Nakajima 1999; 
Vlodavsky, Friedmann et al. 1999) suggested that unlike the family of proteases such as the large 
family of matrix metalloproteases that can digest different components of the ECM, HPSE (also 
referred to as HPSE-1) is known to be the only mammalian endoglycosidase.  The unique 
characteristic of this enzyme makes it an attractive target for treatment of various malignancies. 
Molecular Properties 
The human hpse gene (∼50 kb) is located on chromosome 4q21.3 and is expressed as 5 
and 1.7 kb mRNA species, generated by alternative splicing (Dong, Kukula et al. 2000).  The 5 
kb mRNA form contains 14 exons separated by 13 introns, whereas in the short 1.7 kb form, the 
first and 14th exons have been spliced out.  Sequence analysis suggested that HPSE is highly 
conserved across mammalian species with about 80% homology between human, rat, mouse and 
bovine sequences and about 60% homology with the chicken sequence (Goldshmidt, Zcharia et 
al. 2001; Parish, Freeman et al. 2001).  The human hpse cDNA contains an open reading frame 
encoding a polypeptide of 543 amino acids with a predicted molecular weight of 61.2 kDa.  The 
active HPSE purified from placenta, platelets and various cell lines lacked the N-terminal 
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domain of 156 amino acids (Toyoshima and Nakajima 1999; Vlodavsky, Friedmann et al. 1999; 
Goldshmidt, Zcharia et al. 2001; Parish, Freeman et al. 2001) suggesting post-translational 
modification.  Thus, HPSE is synthesized as an inactive precursor which is processed 
proteolytically to generate an active enzyme (Fairbanks, Mildner et al. 1999).  The intervening 6 
kDa peptide (Ser110–Gln157) is excised to generate a heterodimer consisting of a 50 kDa 
subunit (Lys158–Ile543) attached noncovalently to an 8 kDa peptide (Gln36–Glu109) 
(Fairbanks, Mildner et al. 1999; Levy-Adam, Miao et al. 2003; McKenzie, Young et al. 2003) 
(Fig. 1.7).  Notably, the 8 kDa N-terminal sequence is required for enzymatic activity; when 
expressed alone, the truncated 50 kDa (Lys158–Ile543) protein fails to demonstrate any 
enzymatic activity (Hulett, Hornby et al. 2000).  Co-transfection and immunoprecipitation 
studies further indicate that heterodimer formation is essential for enzymatic activity as it is only 
obtained by co-expression of both the 8 and 50 kDa subunits (Levy-Adam, Miao et al. 2003; 
McKenzie, Young et al. 2003).  Using site-directed mutagenesis techniques to determine the 
amino acids critical for cleavage at Glu109– Ser110 (site 1) and Gln157–Lys158 (site 2), 
Abboud-Jarrous et al. 2005 reported that mutations generated at site 1 and its flanking regions 
did not effect HPSE processing or activity.  Alternatively, substitution of Tyr156 at site 2 by 
alanine or glutamine rendered HPSE inactive and the enzyme was also processed incorrectly 
(Abboud-Jarrous, Rangini-Guetta et al. 2005).  This study also pointed out that a tyrosine at 
position 2 (P2) of the cleavage site (Gln157–Lys158) was absolutely necessary for proper HPSE 
processing and activation, resembling the cleavage specificity of cathepsin L (Abboud-Jarrous, 
Rangini-Guetta et al. 2005).  Interestingly, incubation of the purified latent 65 kDa HPSE with 
cathepsin L generated appropriately processed and active HPSE, composed of the 50 and 8 kDa 
subunits.  This observation was repressed in the presence of a specific, cell permeable inhibitor  
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Figure 1.7:  Primary structure and predicted 3D structure of the HPSE heterodimer (Ilan, 
Elkin et al. 2006).  N-terminal signal peptide (SP, Met1–Ala35) is removed from pre-proHPSE 
after entering the ER.  The protein is then subjected to glycosylation at six N-glycosylation sites 
( ) in the Golgi apparatus followed by secretion as a latent 65 kDa protein (upper panel).  
Proteolytic removal of the linker domain (Ser110–Gln157) results in an 8 kDa (Gln36–Glu109) 
and 50 kDa (Lys158–Ile543) protein subunits (middle panel) that heterodimerize to yield the 
active enzyme.  A predicted three-dimensional structure of the HPSE heterodimer (bottom panel) 
was created based on homology with the endo 1,4-β-xylanase.  The 8 (yellow) and 50 kDa (gray) 
subunits and glutamic acid residues 225 and 343 are illustrated (bottom panel) at the enzyme 
active site (red). The heparin binding domains (HBD 1 & 2, blue and green) are in close 
proximity to the enzyme active site (red) (Hulett, Hornby et al. 2000; Nardella, Lahm et al. 2004; 
Ilan, Elkin et al. 2006) [reproduced with permission from Ilan, N., Elkin, M. et al. (2006), 
"Regulation, function and clinical significance of heparanase in cancer metastasis and 
angiogenesis." Int J Biochem Cell Biol 38(12): 2018-39]. 
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of cathepsin L (Abboud-Jarrous, Rangini-Guetta et al. 2005).  It is possible that cathepsins other 
than cathepsin L may activate proHPSE in a cell- and tissue-dependent manner.  The predicted 
amino acid sequence of HPSE also suggested six putative N-glycosylation sites on the 50 kDa 
subunit signifying further possible post-translational modification needed for enzymatic activity.  
Interestingly, glycosylation did not affect enzymatic activity but it was found to be essential for 
secretion of HPSE (Simizu, Ishida et al. 2004). 
HPSE enzyme activity is also closely regulated by pH, achieving maximal activity under 
acidic conditions at an optimum range between pH 5.5-6.8 (Mckenzie 2003) that correlates well 
with the concept that the microenvironment in tumors is usually more acidic than in normal 
tissues.  This acidity of the tumor microenvironment is also found within hypoxic areas of 
growing tumors (Tannock et al., 1989).  Upon activation in this acidic environment, HPSE 
facilitates the release of several protein modulators that affect cell functions such as migration, 
adhesion, inflammation, and angiogenesis (Sanderson 2005). 
Structure, Processing and Trafficking 
According to sequence alignment and secondary structure prediction, HPSE is thought to 
adopt a TIM (triosephosphate isomerase) barrel fold, similar to other known glycosyl hydrolases 
(Hulett, Hornby et al. 2000).  A TIM barrel fold is usually formed by eight alternating α-helices 
and β-strands.  The 50 kDa HPSE subunit is believed to have six α/β units and, an α/β/α element 
is predicted to be contributed by the 8 kDa subunit (Nardella, Lahm et al. 2004) (Fig. 1.7).  This 
family of enzymes uses a general acid catalysis mechanism for the hydrolysis of glycosidic 
bonds that requires two critical residues, a proton donor and a nucleophile, both of which seem to 
be conserved in HPSE at Glu225 and Glu343, respectively (Hulett, Hornby et al. 2000).  Site-
directed mutagenesis of these two residues inhibited HPSE activity completely, signifying that 
  25 
 
HPSE employs a catalytic mechanism characteristic of GH-A glycosyl hydrolyses (Hulett, 
Hornby et al. 2000) to cleave the linkage between the glucuronic acid and N-acetylglucosamine 
of the HSGAG (Nakajima, Irimura et al. 1983). 
When added externally to cells in culture, pro-HPSE is rapidly internalized and converted 
into the active enzyme suggesting that processing may occur at the cell surface (Vlodavsky and 
Friedmann 2001; Nadav, Eldor et al. 2002), but recent studies indicate that HPSE processing 
occurs intracellularly in acidic vesicles, most likely lysosomes (Gingis-Velitski, Zetser et al. 
2004a; Zetser, Levy-Adam et al. 2004; Vreys, Delande et al. 2005). Following exogenous 
addition, both active and latent forms of the enzyme localize in endocytic vesicles, suggesting 
that processing does not occur at the cell surface (Zetser et al., 2004).  Despite its localization in 
the lysosome, HPSE has a half life of about 30 h (Gingis-Velitski, Zetser et al. 2004a) and in 
response to proper stimuli it may be secreted from the lysosomes (Shafat, Vlodavsky et al. 2006).  
HPSE uptake is also mediated by cell surface HS in primary fibroblasts and endothelial cells, as 
well as in tumor cells to restrict its availability on the cell-surface (Nadav, Eldor et al. 2002; 
Gingis-Velitski, Zetser et al. 2004a; Gingis-Velitski, Zetser et al. 2004b; Zetser, Levy-Adam et 
al. 2004).  When HPSE was overexpressed in HS-deficient cells, latent enzyme accumulated in 
the culture medium along with decreased levels of the active intracellular processed enzyme 
suggesting that the latent protein is secreted first followed by HS-mediated endocytosis (Gingis-
Velitski, Zetser et al. 2004a) (Fig. 1.8).  Sequence alignment indicated two heparin binding 
domains in HPSE at Lys158–Asp162 at the N-terminus, and at Pro271–Met278 of the 50 kDa 
subunit (Levy-Adam, Abboud-Jarrous et al. 2005).  A peptide containing the Lys158–Asp162 
sequence (KKDC) displayed firm binding to heparin and HS and repressed HPSE uptake and 
activity possibly due to competition with the HS substrate (Levy- Adam, Abboud-Jarrous et al.  
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Figure 1.8.  An anticipated model for HPSE biosynthesis, processing and trafficking (Ilan, 
Elkin et al. 2006).  1) Pre-proHPSE is targeted to ER by its own signal peptide (Met1–Ala35, 2) 
The 65 kDa pro-heparanase is then transferred to Golgi apparatus and is subsequently secreted 
via exocytosis, a step that is specifically inhibited by Brefeldin A (BFA) (Nadav, Eldor et al. 
2002).  3) Following secretion, HPSE quickly interacts with cell membrane HSPG such as the 
syndecans (Gingis-Velitski, Zetser et al. 2004a), mannose-6 phosphate receptor or LRP (Vreys, 
Delande et al. 2005), 4) followed by a rapid endocytosis of the HPSE-HSPG complex which 
seems to reside in endosomes; this is inhibited by cytochalasin D (Cyto. D) (Nadav, Eldor et al. 
2002), or heparin (Gingis-Velitski, Zetser et al. 2004a).  5) Conversion of endosomes to 
lysosomes leads to processing and activation of HPSE which, in turn, participate in the turnover 
of HS in the lysosomes.  HPSE processing and activation is specifically inhibited by chloroquine 
and Bafilomycin A that are inhibitors of lysosomal proteinases (Zetser, Levy-Adam et al. 2004). 
6) HPSE at perinuclear lysosomal vesicles arises possibly by direct conversion of secretory 
vesicles to endosomes (dashed arrow).  7) Lysosomal HPSE may translocate to the nucleus, 
where it could influence gene transcription, leading to differentiation of carcinoma cells 
(Takaoka, Naomoto et al. 2003; Ohkawa, Naomoto et al. 2004), or 8) it can be secreted in 
response to local or systemic cues.  Secretion of active HPSE is repressed by PKC inhibitors 
(Bis), and P2Y receptor antagonists (MRS, PPADS) (Shafat, Vlodavsky et al. 2006).  9) The 
latent secreted HPSE can also interact with HPSE-binding proteins (HBP) and stimulate 
signaling components such as Akt, p38, Src, Pyk2 and integrins, leading to enhanced cell 
adhesion, migration, VEGF induction and angiogenesis (Goldshmidt, Zcharia et al. 2003; Zetser, 
Bashenko et al. 2003; Gingis-Velitski, Zetser et al. 2004b; Sotnikov, Hershkoviz et al. 2004; 
Zetser, Bashenko et al. 2006) [reproduced with permission from Ilan, N., Elkin, M. et al. (2006), 
"Regulation, function and clinical significance of heparanase in cancer metastasis and 
angiogenesis." Int J Biochem Cell Biol 38(12): 2018-39]. 
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2005).  A KKDC deletion mutation resulted in intracellular buildup of the latent form due to 
impaired secretion, but deletion of the Pro271–Met278 sequence caused accumulation of the pro-
enzyme in the medium, suggesting an additional role of HS in HPSE uptake and processing 
(Levy-Adam, Abboud-Jarrous et al. 2005).  The KKDC sequence also seems to dwell in close 
proximity to HPSE active sites (Glu225 and Glu343) in a micro pocket domain (Fig. 1.7) (Hulett, 
Hornby et al. 2000).  Two additional cell surface receptors, low-density lipoprotein receptor-
related protein (LRP) and the mannose 6-phosphate receptor, have also been recognized as 
mediating HPSE uptake (Vreys, Delande et al. 2005). 
Regulation of Gene Expression 
Promoter methylation has an important role in HPSE gene transcription.  Tumor-derived 
cell lines exhibiting HPSE activity harbor at least one unmethylated allele (Shteper, Zcharia et al. 
2003; Ogishima, Shiina et al. 2005a; Ogishima, Shiina et al. 2005b).  Ogishima et al. (2005b) 
have also demonstrated a correlation between HPSE expression levels in bladder and prostate 
carcinomas and the expression levels of early growth response 1 (EGR1), a transcription factor 
important for HPSE gene transcription (de Mestre, Khachigian et al. 2003; de Mestre, Rao et al. 
2005).  HPSE promoter contains four putative estrogen response elements, and estrogen 
stimulates HPSE mRNA expression in estrogen receptor-positive human breast carcinoma cells 
(MCF7), but not in estrogen receptor-negative human breast carcinoma (MDA-MB-231).  
Estrogen also enhances HPSE-mediated angiogenesis in vivo (Elkin, Cohen et al. 2003).  CREB 
(cyclic adenosine monophosphate binding protein), another transcription factor important in 
tumor progression, regulates HPSE expression and activity in melanoma in a positive manner 
(Aucoin, Reiland et al. 2004).  In addition, the hpse gene is constitutively repressed by wild type 
p53 under normal conditions.  This could explain an upregulation of HPSE expression observed 
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in various primary and metastatic cancers where p53 is often mutated or inactivated in the course 
of tumor progression (Baraz, Haupt et al. 2006). 
Function 
HPSE has important normal physiological functions such as neovascularization, 
inflammation, autoimmunity, and embryonic implantation (Matzner, Vlodavsky et al. 1992; 
Dempsey, Brunn et al. 2000; Parish, Freeman et al. 2001; Vlodavsky and Friedmann 2001; 
Revel, Helman et al. 2005).  It also has essential pro-angiogenic and pro-metastatic roles 
attributed to its enzymatic activity.  A critical early event during angiogenesis is degradation of 
the subendothelial basement membrane (BM) which is followed by endothelial cell (EC) 
migration toward the angiogenic stimulus.  HPSE may directly aid EC invasion and sprouting by 
degrading HS in the BM and by releasing HS-bound angiogenic growth factors (i.e., FGF2, 
VEGF) from the ECM (Folkman, Klagsbrun et al. 1988) that could indirectly facilitate EC 
proliferation and migration (Vlodavsky, Miao et al. 1996; Elkin, Ilan et al. 2001).  Furthermore, 
HPSE-degraded bio-active HS fragments can stimulate angiogenesis by modifying activities of 
angiogenic growth factors (Reiland, Kempf et al. 2006).  HPSE activity correlates with the 
metastatic potential of tumor cells; sub lines with higher metastatic potential exhibit a higher 
enzymatic activity than low- or non-metastatic cells (Hulett, Freeman et al. 1999; Vlodavsky, 
Friedmann et al. 1999; Yang, MacLeod et al. 2005).  Overexpression of HPSE by transfection or 
an adenoviral gene delivery method increased invasive and metastatic properties in cancers of 
esophagus, lung and in melanoma (Uno, Fujiwara et al. 2001; Roy, Reiland et al. 2005).  
Conversely antisense, siRNA and ribozyme technologies-mediated reduction of HPSE 
expression led to a decrease in invasive properties in vitro and in vivo (Uno, Fujiwara et al. 2001; 
Edovitsky, Elkin et al. 2004; Roy, Reiland et al. 2005).  Interestingly, exceedingly elevated 
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HPSE expression levels can also inhibit tumorigenesis, probably due to extensive cell-surface 
remodeling (Zetser, Bashenko et al. 2003; Reiland, Kempf et al. 2006). 
HPSE also exerts non-enzymatic activities, independent of its involvement in ECM 
degradation and remodeling.  Inactive HPSE expressed on the cell-surface leads to firm cell 
adhesion, indicating an involvement in cell–ECM interaction (Goldshmidt, Zcharia et al. 2003).  
Inactive HPSE also enhances Akt signaling and promotes PI3K- and p38-dependent endothelial 
cell migration and invasion (Gingis-Velitski, Zetser et al. 2004b). 
Inhibitors 
Low-molecular-weight heparin (LMWH) prolongs survival in patients with cancer 
according to recently published randomized-controlled trials (RCTs) in which four different 
types of LMWH improved the survival in patients with advanced cancer (Kakkar, Levine et al. 
2004; Klerk, Smorenburg et al. 2005; Rickles 2006).  LMWH either directly affects tumor 
growth and metastasis and/or indirectly inhibits thrombin generation, the latter being widely 
implicated in tumorigenesis (Rickles, Patierno et al. 2003).  Heparin may also inhibit metastasis 
by blocking platelet–tumor cell interactions, thus inhibiting aggregates of tumor cells being 
trapped in the microvasculature or by blocking selectin-mediated cell–cell interactions to prevent 
tumor cells from attaching to the vascular endothelium (Borsig, Wong et al. 2001; Borsig 2004).  
An array of HPSE inhibiting molecules, including peptides, small molecules, neutralizing 
antibodies, modified non-anti-coagulant species of heparin, and several polyanionic molecules 
(laminarin sulfate, suramin analogues and PI-88) have been developed (Marchetti, Reiland et al. 
2003; Ferro, Hammond et al. 2004; Simizu, Ishida et al. 2004; Ilan, Elkin et al. 2006).  Abnormal 
expression of HPSE in malignancy, combined with the fact that it is the only mammalian 
glycosidase involved in tumorigenesis, makes it an attractive target for cancer chemotherapy. 
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Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor in Angiogenesis 
The term angiogenesis was first introduced by Judah Folkman in 1971 to propose that 
tumor growth beyond a certain dimension (0.2-2.0 mm or about 105-106 cells) required formation 
of new blood vessels from the pre-existing vascular network (Folkman 1971; Folkman, Merler et 
al. 1971).  Angiogenesis contributes to development of the cardiovascular system during 
embryogenesis, and is essential in adult life for wound healing and the female reproductive 
cycle.  Turnover of endothelial cells is sluggish under normal physiological circumstances; 
however, tumor endothelial cells divide rapidly and frequently during neoangiogenesis (Folkman 
1995; Iozzo and San Antonio 2001).  Angiogenesis is a multi-step process that initiates with the 
localized degradation of the basement membrane by activated endothelial cells that migrate and 
proliferate.  This leads to formation of solid endothelial cell sprouts into the stromal space which 
grow into vascular loops.  Finally capillary tubes are developed with the formation of tight 
junctions and deposition of new basement membrane (Carmeliet 2000).  The transformation of 
preangiogenic phenotype to the angiogenic phenotype by an “angiogenic switch” results from an 
imbalance between the pro- and anti-angiogenic factors that are released primarily by 
surrounding pericytes and lymphocytes (Ranieri and Gasparini 2001).  A large number of these 
factors are known to bind to heparin/HS on HSPG, including key angiogenic growth factors such 
as the FGFs and VEGFs (Hanahan and Folkman 1996; Iozzo and San Antonio 2001). 
FGF1 and FGF2 were the first two prototypic heparin-binding angiogenic growth factors 
to be identified, purified and sequenced (Folkman, Merler et al. 1971; Maciag, Mehlman et al. 
1984; Shing, Folkman et al. 1984).  Since then, 22 structurally-related members of the FGF 
family have been identified (Itoh and Ornitz 2004).  FGFs induce cell proliferation and/or 
differentiation of mesodermal or neuroectodermal origin, including endothelial cells and 
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melanoma following interaction with heparan-sulfate proteoglycans (HSPG) and tyrosine kinase 
FGF receptors (FGFRs) (Burgess and Maciag 1989; Gospodarowicz 1991; Rapraeger, Krufka et 
al. 1991; Dellian, Witwer et al. 1996).  In vivo, FGF is known to mediate growth and 
neovascularization of solid tumors (Folkman and Klagsbrun 1987).  Antisense FGF1 and FGF2 
receptor cDNAs inhibit growth and angiogenesis in human melanoma (Wang and Becker 1997).  
Cells expressing FGF-2 are known to be more angiogenic than the nonexpressing counterpart 
(Konerding, Fait et al. 1998).  FGF2 is stored in the ECM complexed with the HS (low affinity) 
on HSPG and this complex formation is required for FGF2 receptor binding (high affinity 
ternary complex) and subsequent signaling and activity (Reiland and Rapraeger 1993; Rapraeger 
1995). 
VEGF (vascular endothelial growth factor), also known as vascular permeability factor 
(VPF) (Senger, Galli et al. 1983; Senger, Perruzzi et al. 1986) was originally described as a 
highly specific mitogen for endothelial cells (Leung, Cachianes et al. 1989) and as a potent 
inducing agent for angiogenesis and vasculogenesis in a variety of physiological and 
pathological conditions (Plate, Breier et al. 1992; Ferrara, Winer et al. 1993; Tuder, Flook et al. 
1995; Ferrara and Davis-Smyth 1997).  Inhibition of VEGF signaling by VEGF antagonists, or 
antisense VEGF, or dominant negative VEGFR, impaired tumorigenesis in vivo (Kim, Li et al. 
1993; Millauer, Shawver et al. 1994; Saleh, Stacker et al. 1996; Yano, Shinohara et al. 2000).  
The VEGF family of proteins includes VEGF A through E and placenta growth factor (Neufeld, 
Cohen et al. 1996; Ranieri, Patruno et al. 2006).  VEGF A is the most well studied one and one 
of its splice variants, VEGF165, is the most potent and widely expressed isoform known (Plouet, 
Moro et al. 1997).  VEGF165 is secreted as a disulfide-linked homodimer with two identical 
heparin-binding sites. Interactions with HS regulate the diffusion, half-life, and affinity of 
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VEGF165 for its signaling receptors.  VEGF165 binding to VEGFR1 is dependent on cellular 
HSPG; exogenous heparin/HS cannot fully compensate for the loss of cell-surface HS, 
suggesting that HSPG play a role in VEGF165 presentation (Terman, Khandke et al. 1994; 
Cohen, Gitay-Goren et al. 1995). VEGF165 can bind VEGFR2 in the absence of HS, but this 
interaction is enhanced by cellular or exogenous heparin/HS (Terman, Khandke et al. 1994; 
Gitay-Goren, Cohen et al. 1996) suggesting that HS on HSPG regulate the interaction of VEGF 
to VEGFR and consequent biological activity (Schlessinger, Lax et al. 1995). 
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CHAPTER II 
ANTISENSE-MEDIATED SUPPRESSION OF HEPARANASE GENE 
INHIBITS MELANOMA CELL INVASION* 
 
INTRODUCTION 
Mechanisms responsible for melanoma progression to highly aggressive metastatic 
disease are not fully understood.  However, it is known that proteolytic enzymes play important 
roles due to their involvement in extracellular matrix (ECM) disassembly, which allows tumor 
cells to invade into distant organs.  Heparan sulfate proteoglycans (HSPG) (Iozzo 2001) are now 
recognized as cell surface/ECM active biologic modulators (Kjellen and Lindahl 1991), and their 
degradation at the level of heparan sulfate glycosaminoglycan chains (HS) has significant 
regulatory consequences in cancer metastasis.  Elevated levels of heparanase (HPSE-1) are 
known to be associated with brain-metastatic melanoma (Marchetti, Menter et al. 1993; 
Marchetti, McQuillan et al. 1996; Marchetti and Nicolson 2001; Marchetti 2002; Marchetti 
2002).  HPSE-1 is an endo-β-D-glucuronidase (Nakajima, Irimura et al. 1988) involved in the 
degradation of cell surface/ ECM HSPG of a wide range of normal and neoplastic tissues (Hulett, 
Freeman et al. 1999; Kussie, Hulmes et al. 1999; Toyoshima and Nakajima 1999; Vlodavsky, 
Friedmann et al. 1999; Sasaki, Higashi et al. 2004) and a molecular determinant of metastatic 
events.  The enzymatic activity of HPSE-1 is characterized by specific intrachain HS cleavage of 
glycosidic bonds with a hydrolase (but not eliminase) type of action, therefore facilitating the 
release of several protein modulators of cell function, including migration, adhesion, inflamm-       
--------------------------------------------------------------------------------------------------------------------- 
* Reprinted with permission of Dr. A.  Rehamtulla, editor of Neoplasia, from Roy M, Reiland J, 
Murry B P, Chouljenko V, Kousoulas K G, Marchetti D. (2005)  Antisense-Mediated 
Suppression of Heparanase Gene Inhibits Melanoma Cell Invasion. Neoplasia; 7(3): 253-62. 
49 
ation, angiogenesis, embryogenesis, invasion and metastasis (Parish, Coombe et al. 1987; 
Nakajima, Irimura et al. 1988; Vlodavsky, Bar-Shavit et al. 1991; Hulett, Freeman et al. 1999; 
Kussie, Hulmes et al. 1999; Toyoshima and Nakajima 1999; Vlodavsky, Friedmann et al. 1999; 
Vlodavsky and Friedmann 2001; Zetser, Bashenko et al. 2003; Sasaki, Higashi et al. 2004).  
Secondly, HPSE-1 levels have been found to be increased in sera and urine of human patients 
with metastatic cancers (Parish, Coombe et al. 1987; Nakajima, Irimura et al. 1988; Vlodavsky, 
Bar-Shavit et al. 1991; Hulett, Freeman et al. 1999; Kussie, Hulmes et al. 1999; Toyoshima and 
Nakajima 1999; Vlodavsky, Friedmann et al. 1999; Vlodavsky, Goldshmidt et al. 2001; Kelly, 
Miao et al. 2003; Zetser, Bashenko et al. 2003; Sasaki, Higashi et al. 2004).  Thirdly, HPSE-1 
activity correlates with the metastatic potential of tumor cells in animal models, resulting in 
increased mortality (Vlodavsky, Goldshmidt et al. 2001).   Finally, enhanced HPSE-1 mRNA 
levels correlate with reduced postoperative survival in cancer patients (Vlodavsky, Bar-Shavit et 
al. 1991; Hulett, Freeman et al. 1999; Kussie, Hulmes et al. 1999; Vlodavsky, Friedmann et al. 
1999; Vlodavsky, Goldshmidt et al. 2001; Sasaki, Higashi et al. 2004). 
HPSE-1 from various mammalian sources has been cloned as a single gene family 
(Hulett, Freeman et al. 1999; Kussie, Hulmes et al. 1999; Toyoshima and Nakajima 1999; 
Vlodavsky, Friedmann et al. 1999; Sasaki, Higashi et al. 2004), representing the dominant HS-
degradative enzyme.  Importantly, HPSE-1 regulation has been shown to change metastatic 
properties of tumors (Vlodavsky, Friedmann et al. 1999; Uno, Fujiwara et al. 2001; Zhang, Fu et 
al. 2003). For example, an upregulation of the enzyme has been shown to increase the metastatic 
properties of tumor cells (Vlodavsky, Friedmann et al. 1999; Uno, Fujiwara et al. 2001).  
Conversely, downregulating HPSE-1 by antisense strategies (Uno, Fujiwara et al. 2001; Zhang, 
Fu et al. 2003) demonstrated a reduction in the invasive properties of neoplastic cells.   
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Evidence has also demonstrated that HPSE-1 is a potential target for antimetastasis drugs 
because of its critical roles in angiogenic and invasive processes: treatment of experimental 
animals with HPSE-1 inhibitors considerably reduced the incidence of tumor invasion and 
angiogenesis in animal models (Parish, Coombe et al. 1987; Marchetti, Reiland et al. 2003).  
Extensive available animal and clinical data suggest that HPSE-1 may play an important role in 
the progression of a variety of human tumors.  Nevertheless, the possible role(s) of HPSE-1 in 
tumor progression at the molecular and cellular levels is poorly understood. 
These observations led us to hypothesize that inhibition of HPSE-1 expression could 
inhibit tumor cell invasion by metastatic melanoma cells.  Here we demonstrate that an 
adenoviral vector expressing the full-length human heparanase gene in an antisense orientation 
specifically inhibits HPSE-1 expression as well as its invasiveness, leading to a reduction of 
invasive capabilities by metastatic melanoma cells in vitro and in vivo.  Our results further 
support the fact that inhibiting HPSE-1 can change the invasive properties of melanoma cells like 
others have found in lung or breast carcinoma cell lines. 
MATERIALS AND METHODS 
Materials 
Heparan sulfate (HS) from bovine kidney was acquired from Sigma Chemical Company 
(St.  Louis, MO).  DMEM and Ham’s F-12 nutrient medium and trypsin-EDTA were purchased 
from Gibco (Grand Island, New York, NY), and FBS from Hyclone Laboratories (Logan, UT).        
Human recombinant HPSE-1 was kindly provided by Dr.  Edward McKenzie (McKenzie, Young 
et al. 2003).  The polyclonal antibodies to human HPSE-1 were generously provided by Dr. 
Laurie A. Dempsey (Mayo Clinic, Rochester, Minnesota) and Dr. Robert L. Heinrikson 
(Pharmacia-Upjohn Inc., Kalamazoo, Michigan). 
51 
Transwell cell culture chambers were purchased from Corning Incorporated Life 
Sciences (Acton, MA), while MatrigelTM was obtained from BD Biosciences Discovery Labware 
(Bedford, MA) and fibronectin from ICN Biochemical (Irvine, CA).  All other chemicals used 
were reagent grade or better. 
Cells and Tissue Culture Conditions 
Early-passage melanoma cells with varying metastatic abilities, both of murine 
(B16B15b line (Nakajima, Irimura et al. 1983) and human origin (70W line) (Ishikawa, Dennis 
et al. 1988; Ishikawa, Fernandez et al. 1988) were maintained as monolayer cultures in a 1:1 
(v/v) mixture of DMEM/F-12 supplemented with 10% (v/v) FBS and 5 mM sodium butyrate 
(B16B15b) or 10% (v/v) FBS (70W).  B16B15b and 70W metastatic melanoma cells (lung being 
the primary colonization site) were chosen as a source of HPSE-1 because they are highly 
invasive and produce HPSE-1 at elevated levels versus their respective parental counterparts 
(Marchetti, Menter et al. 1993; Marchetti, McQuillan et al. 1996).  Cells were maintained at 
37°C in a humidified 5% CO2/95% air (v/v) atmosphere and passaged using 2 mM EDTA 
(B16B15b) or trypsin-EDTA (70W) before reaching confluence.  The transformed embryonic 
kidney cell line 293 was grown in DMEM/F-12, supplemented with 10% FBS and penicillin 
(100 units/ml), and streptomycin (100 µg/ml).  The 293 cells were used for the production of 
adenoviral vectors (Uno, Fujiwara et al. 2001). 
Construction of Recombinant Adenovirus Containing the Human Heparanase Gene 
An adenovirus expression vector kit (Takara Biomedicals Inc., Tokyo, Japan) was used to 
generate recombinant adenovirus for the expression of human HPSE-1 gene in both sense and 
antisense orientations.    Replication-deficient, E1- and E3-deleted recombinant adenovirus 
serotype 5 (Ad5) was used as the viral backbone.   Plasmid DNA containing the cloned HPSE-1 
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gene and synthetic oligonucleotides Hep-5’ (complementary to the 5’ end of the gene) and Hep-
3’ (complementary to the 3’ end of the gene) were used to produce PCR products encompassing 
the HPSE-1 sequence (1632 bp).   PCR products were treated with T4 DNA polymerase to 
generate uniformed blunt ends required for the ligation reaction into pAxCAwt cosmid provided 
by the Takara kit.    After cloning the HPSE-1 gene into cosmid vector, availability of the 
recombinant cosmids containing the target gene in sense (5’ - 3’ under the CAG promoter of the 
vector) and antisense (3’ - 5’) orientations were confirmed by restriction analysis.     Cosmid 
DNAs were produced in large quantities and after gradient purification were used for 
cotransfection with adenovirus genomic DNA-terminal protein complex (DNA-TPC provided by 
the kit) into 293 cells.    Following the kit protocol, recombinant adenoviruses expressing human 
HPSE-1 in both sense (Ad-S/hep) and antisense (Ad-AS/hep) orientations were generated.    
Integrity of these recombinant viruses was confirmed by PCR and restriction analysis.    The E1-, 
E3-deleted, replication deficient adenovirus pAd5-Blue was used as the control vector.    Viral 
titer was quantified by determination of the 50% infectivity on tissue culture (TCID 50) in 293 
cells. 
Adenoviral Infection  
  70W and the B16B15b cells were plated on 100 mm dishes (106 cells/dish).    Twenty 
four hours later, cells were washed twice with PBS containing 2 mM EDTA, and infected with 
virus diluted in serum-free DMEM/F-12.   To maximize cell viability and protein expression, 
cells were infected with the viral vectors at a multiplicity of infection (M.O.I.) of 30-50.     Plates 
were then incubated at 37°C for 1 hr, rocking gently every 10 min.  Infection was terminated by 
adding culture medium containing penicillin (100 units/ml) and streptomycin (100 µg/ml).  Cells 
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were then incubated at 37oC for an appropriate period of time.  Immunofluorescent control 
experiments were performed to confirm cell infectivity of our adenoviral vectors. 
Reverse Transcription (RT) PCR Analysis 
Total RNA was isolated from cells using RNeasy kit (Qiagen Inc., Valencia, CA).  
Briefly, reverse transcription was performed at 42°C for 1 hour, and PCR was performed using 
specific primers (25 µl final volume).       The following specific primers were used: HPSE-1 
sense (HPSE-1-S: 5'-TTC GAT CCC AAG AAG GAA TCA AC-3') and HPSE-1 antisense 
(HPSE-1-AS: 5'- TAC ATG GCA TCA CTA C -3'); for the sequence just after the inserted 
fragment in the vector (Ad5 pax: 5'-ATC GAT TCT AGA CTA GTT TAA TTA ATT T-3'); 
control glyceraldehyde-3-phosphate dehydrogenase, sense (5'- TGA AGG TCG GAG TCA ACG 
GAT TTG GT -3') and antisense (5'- CAT GTG GGC CAT GAG GTC CAC CAC -3').    The 
amplification reaction for HPSE-1, Ad-S/hep and Ad-AS/hep specific constructs involved 35 
cycles of denaturation at 95°C for 45 seconds, annealing at 52°C for 1 min, and 72°C for 1 min.    
The amplification for GAPDH reaction involved 35 cycles of denaturation at 94oC for 30 
seconds and annealing at 68oC for 3 min in the GeneAmp PCR-system 9700 (Applied 
Biosystems, Foster City, CA).  PCR products were subsequently resolved on 1% agarose gels 
and visualized by ethidium bromide staining. 
Western Blot Analysis  
Cells were plated (106 cells/plate) on 100 mm dishes and allowed to attach and grow for 
24 hr.  Cells were subsequently infected with Ad-S/hep, Ad-AS/hep or pAd5-Blue control vector 
and incubated for 36-48 hours.  They were then released and centrifuged (300 rpm for 5 min) and 
resuspended in lysis buffer [TBS (pH 7.4) containing Triton-X 100 (0.5%), leupeptin (10 µg/ml), 
pepstatin (10 µg/ml) and PMSF (0.2 mM)] at a density of 108 cells/ml.  Cells were subsequently 
54 
vortexed and kept on ice for 10 min followed by centrifugation for 10 min at 13,000 rpm at 4oC.  
Supernatant was collected and protein concentration was determined by the BCA assay.  Protein 
samples (60-90 µg) were then incubated at 100°C for 10 min with Laemmli sample buffer 
(Laemmli 1970)  and separated on 10% Criterion gels (Tris-HCl, Bio-Rad Laboratories, 
Hercules, CA).  Gels were transferred to a PVDF membrane (Pierce Endogen Inc., Rockford, IL) 
and  incubated overnight (18 hrs) in a blocking reagent  [3% (w/v) non-fat dry milk, 0.5% (w/v) 
BSA, 0.3% (v/v) Tween-20 in PBS, pH 7.5].  HPSE-1 protein was labeled using anti-HPSE-1 
PAb (1: 5,000 dilution) (Mayo Clinic, Rochester, Minnesota) in 3% (w/v) non-fat dry milk, 0.5% 
(w/v) BSA, washed for 1 hr with 6-8 changes of 0.5% IGE-PAL (CA-630, Sigma Chemical 
Company, St.  Louis, MO) in Tris buffer (20 mM Tris, 150 mM NaCl, pH 7.4), and then 
incubated with horseradish peroxidase-anti-rabbit IgG (1: 5,000 dilution; Accurate Scientific, 
Westbury, NY).  It was subsequently washed and developed using the Super-signal west femto 
maximum sensitivity substrate (Pierce Endogen Inc., Rockford, IL).  Dual-Color Precision Plus 
Protein Standards (Bio-Rad Laboratories Inc., Hercules, CA) were used as molecular weight 
markers.  Labeling was detected and quantified using a Versadoc imaging system (Quantity One, 
Bio-Rad Laboratories Inc., Hercules, CA). 
HPSE-1 Activity Assays   
HPSE-1 activity was determined by degradation of FITC-HS using high-speed gel 
permeation column chromatography (HPLC) as previously described (Toyoshima and Nakajima 
1999; Reiland, Sanderson et al. 2004).  Briefly, cell-lysates (80 µg cell lysate/µg of HS) were 
prepared as described above and incubated with FITC-HS at 37oC for 18 hr in 100 l of sodium 
acetate (100 mM, pH 4.2).  Reaction was terminated by heating samples for 100oC for 15 min.  
HS products yielded by HPSE-1 reaction were analyzed by size exclusion chromatography 
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performed on a HP1090 liquid chromatograph with a photodiode array detector (Agilent 
Technologies Inc., Wilmington, DE) and a HP1046 programmable fluorescence detector 
(Agilent Technologies Inc., Wilmington, DE).  Samples (25 µl) were injected on a TSK-GEL 
3000SWXL column (5 µm, 7.8 mm x 30 cm) with a TSK-GEL SWXL guard column (5 µm, 6.0 
mm x 4.0 cm) from Tosoh Bioscience (Montgomeryville, PA) at an ambient temperature (25oC).  
Samples were isocratically eluted using Tris-HCl (25 mM), NaCl (150 mM), pH 7.5 at a flow 
rate of 0.5 ml/min with a sample splitter placed between the column and detectors to maintain a 
column pressure of less than 70 bar.  Fluorescence was monitored with excitation at 490 nm and 
emission at 520 nm, then data was processed and peaks were integrated using HP ChemStation 
software (Agilent Technologies Inc., Wilmington, DE).  HPSE-1 activity was determined by 
measuring the decrease in fluorescence intensity in the first one-half area of the intact FITC-HS 
peak chromatogram.  The retention times were calculated from the highest peak of the 
chromatograms. 
Alternatively, a commercial heparan degrading enzyme assay kit (Takara Mirus 
Biomedical Inc., Madison, WI) was used to determine HPSE-1 activity in melanoma cells 
(Reiland, Sanderson et al. 2004).  Indicated amounts of cell-lysate were incubated with 
biotinylated-HS at 37oC for 45 min and HPSE-1 activity determined by an ELISA type assay.  
Color was developed using the substrate supplied in the kit and plates were read at 450 nm using 
a microplate reader (EL 808, Bio-Tek Instruments Inc., Winooski, VT).   
Chemoinvasion Assays 
Invasive properties of melanoma cells  were assayed by Boyden’s chambers as previously 
described (Marchetti, Menter et al. 1993).   Briefly, cell invasion was assayed using Transwell 
cell culture chambers (12 µm pore size, 12 mm diameter) coated with MatrigelTM (diluted as 38 
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µg /ml in cold DMEM/F-12 with P/S, 100 µl final coating volume) that was applied to the upper 
filter surface and allowed to dry before use.  Cells were plated on day 1 and after 24 hours were 
infected with Ad-S/hep, Ad-AS/hep or with the control vector pAd5-Blue as described above.      
Twenty four hours later, cells were released from the culture plate and added to the upper 
chamber of invasion plates (1.2 x 105 cells/chamber) in serum-free DMEM/F-12.  Lower 
chambers contained n-formyl-l-methyl-l-leucine-l-phenylalanine (5 nM) in DMEM/F-12 with 
10% (v/v) FBS and fibronectin (1 µg/ml) as chemoattractants.  Cells were incubated in invasive 
chambers for 48-72 hrs at 37oC in a humidified 5% CO2/95% air (v/v) atmosphere.  At the end of 
the experiment, tranwell membranes were lifted from the wells carefully without touching the 
bottom.  Non-invasive cells were wiped from the upper chamber with a cotton swab and invasive 
cells were visualized with Diff-Quick Stain Kit (IMEB Inc., San Marcos, CA) according to 
manufacturer’s instructions.  Briefly, membranes were dipped in solution A (methanol) for 2 
minutes and allowed to air dry.  Membranes were then transferred in solution B (Eosin), dipped 
25 times, transferred in solution C (Azure), and then dipped 25 more times.  After rinsing with 
deionized water, membranes were inverted and allowed to dry.  By using this kit, the nuclei of 
cells are stained blue and cell cytoplasm is stained pink.  The number of invasive cells was 
obtained by counting the nuclei under the microscope. 
In Vivo Tumorigenic Assays 
Human malignant melanoma 70W cells were infected with Ad-S/hep, Ad-AS/hep and 
control pAd5-Blue at a M.O.I. of 50.  Cells were harvested 36 hrs after infection, and 
resuspended in DMEM/F-12 at a density of 5.0 x 106 cells/ml.   6-weeks old  female athymic 
nu/nu mice were injected I.V.  (tail vein) with 200 µl of cell suspension (106 cells) through a 27-
gauge needle.  Mice were euthanized and examined for tumor formation as previously described 
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(Ishikawa, Fernandez et al. 1988).  Metastatic behavior per animal group (number of lung 
nodules and lungs wet weight; N = 15) was then determined.  Additionally, lung tumor tissues 
were saved in formalin and random samples were taken and stained with hematoxylin and eosin 
and analyzed under microscopy. 
Immunohistochemical Analysis 
Immunohistochemical staining was performed using a Vectastain ABC kit (Vector 
Laboratories, Inc., Burlingame, CA) according to the instructions provided by the manufacturer.  
Formalin-fixed, paraffin-embedded tissue sections from in vivo tumorigenic assays were 
mounted on silanized slides and deparaffinized.  Endogenous peroxidase was blocked by 
incubating the sections in 3.0% H2O2 without pretreatment.  After the blocking of nonspecific 
reactivity with rabbit serum for 30 min at room temperature (25oC), sections were incubated at 
4°C for 60 min. with antihuman HPSE-1 rabbit polyclonal antibody raised against human 
heparanase (Pharmacia-Upjohn Inc., Kalamazoo, Michigan).  Following rinsing, slides were 
incubated with biotinylated antirabbit IgG and then with Vectastain ABC reagent.  Peroxidase 
activity was determined using nova red and counterstained with hematoxylin.  As a negative 
control, sections were subjected to normal serum blocking with omission of the primary 
antibody. 
RESULTS 
Detection of HPSE-1 mRNA Expression in Sense or Antisense Orientation 
To examine the significance of human heparanase in metastatic melanoma cell invasion, 
we constructed replication-defective recombinant adenoviruses expressing sense and antisense 
RNA to a full-length human HPSE-1 sequence, Ad-S/hep and Ad-AS/hep, respectively.  Both 
sense and antisense transcripts of HPSE-1 could be detected when HPSE-1-S and HPSE-1-AS 
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primers were used in 70W cells, but not in the B16B15b cells since primers chosen against 
human heparanase did not amplify the murine heparanase.  Strand-specific primer pairs (HPSE-
1-S and Ad5pax, or HPSE-1-AS and Ad5pax) detected the expression of the sense and antisense 
constructs in B16B15b and 70W melanoma cells with Ad-S/Hep or Ad-AS/hep treatment 
respectively (Figure 2.1). 
Modulation of HPSE-1 Protein Levels Following Ad-S/Ad-AS/hep Infection in Melanoma 
Cells 
Western blot analyses were performed to examine the effects of Ad-S/hep and Ad-
AS/hep infection on HPSE-1 protein levels in B16B15b and 70W cells.  Since HPSE-1 is a low-
abundance protein, 60-90 µg of total cell-lysate had to be electrophoresed in order to detect 
adequate HPSE-1 levels (Figure 2.2).  HPSE-1 protein expression increased with Ad-S/hep and 
decreased with Ad-AS/hep treated melanoma cells compared to treatment with control vector 
pAd5-Blue in both B16B15b (Figure 2.2A) and 70W (Figure 2.2B) cells.  HPSE-1 is a 
heterodimer consisting of a 50kDa and a 8kDa band processed from a pro-enzyme precursor 
(65kDa) by proteolytic cleavage and, presence of the 8kDa band is essential for its enzymatic 
activity (Fairbanks, Mildner et al. 1999; Hulett, Freeman et al. 1999; Kelly, Miao et al. 2003).  
We detected the active form of HPSE-1 in the cells; however it migrated slightly slower than its 
predicted molecular weight (50 kDa).  This is consistent with the recent findings by Simizu et al. 
(Simizu, Ishida et al. 2004), and possibly due to post-translational modification in the 
glycosylation of the enzyme.  We also detected a weak band representing the 65kDa inactive 
precursor in B16B15b cells.  Furthermore, we found a two-fold increase in HPSE-1 protein level 
using the Ad-S/hep vector and a 30% decrease with the Ad-AS/hep in the B16B15b cell line 
(Figure 2.2A).  In 70W cells, we observed a 30% increase or decrease in HPSE-1 protein by 
densitometric analysis following Ad-S/hep or Ad-AS/hep treatment, respectively (Figure 2.2B).   
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Figure 2.1.  Expression of human heparanase sense and antisense transcripts in melanoma 
cells.  B16B15b and 70W cell lines were infected with pAd5-Blue (lanes 1 and 4), Ad-S/hep 
(lanes 2 and 5), or Ad-AS/hep vector (lanes 3 and 6) and subjected to RT-PCR analysis 36 hours 
after infection. Two primer pairs, HPSE-1-S/Ad5 pax and HPSE-1-AS/Ad5pax, were designed 
to, respectively, detect sense and antisense transcripts of the human heparanase gene. Both sense 
and antisense transcripts of HPSE-1 could be detected when HPSE-1-S and HPSE-1-AS primers 
were used in 70W cells, but not in the B16B15b cells because the primers chosen against human 
heparanase gene did not amplify murine heparanase. Primers and predicted products are 
indicated at the side of panel. 
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Figure 2.2.  Western blot analysis in melanoma cells for HPSE-1 protein expression.  Cells 
(B16B15b and 70W) were infected with pAd5-Blue (lanes 1 and 4), Ad-S/hep (lanes 2 and 5), or 
Ad-AS/hep (lanes 3 and 6) (see Experimental Procedures section) and analyzed for HPSE-1 
expression after 48 hours. Equal amounts (60 – 90 µg) of protein were loaded on gels and HPSE-
1 protein levels were detected by a rabbit polyclonal antibody and HRP– antirabbit IgG followed 
by use of the Supersignal west femto maximum sensitivity substrate. Bands were visualized on a 
Versadoc imaging system.  Quantification was performed using Quantity One software program 
(Bio-Rad Laboratories Inc.).  (A) Murine B16B15b. (B) Human 70W.   
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HPSE-1 Activity is Upregulated in Ad-S/hep–Treated Melanoma Cells 
We used a specific HPSE-1 activity assay on fluorescein isothiocyanate (FITC)–labeled 
HS in 70W cells.  This assay detects HPLC profile shifts based on the size of HS fragments 
(Toyoshima and Nakajima 1999; Reiland, Sanderson et al. 2004).  Since HPSE-1 cleaves the HS 
chains into discrete fragments, we detected a profile shift when compared to FITC-HS alone 
which was used as negative control (Toyoshima and Nakajima 1999; Reiland, Sanderson et al. 
2004) (data not shown).  We observed a decrease in fragment size in Ad-S/hep-treated 70W cells 
compared to mock-infected cells.  We did not observe a significant difference between Ad-S/hep 
and mock-treated cells since this represents a small shift compared to the total profile area 
(Figure 2.3A).  However, we observed a significant difference in their respective HPLC retention 
times which detect changes in the size of predominant HS fragments (p < 0.02).  This analysis is 
more sensitive to small changes in HS fragment size and showed less activity with Ad-AS/hep-
treated cell lysates (Figure 2.3B).  The Ad-S/hep-treated cell lysates showed a higher retention 
time compared to Ad-AS/hep or mock treatment suggesting that increased digestion of HS 
chains resulted from an augmented HPSE-1 activity following Ad-S/hep treatment in the 70W 
cell line (p< 0.05).  We also performed the ELISA-type assay and found similar changes of 
HPSE-1 activity in response to pAd5-Blue, Ad-S/hep, or Ad-AS/hep treatments (Table 2.1). 
Secondly, we measured HPSE-1 activity in B16B15b and 70W cells co-infected with Ad-
S/hep and Ad-AS/hep, or pAd5-Blue vectors using biotinylated HS and an ELISA kit.  We 
detected a dose-dependent inhibition of HPSE-1 activity with a higher dose of Ad-AS/hep vector 
(Table 2.2).  
Next, we used suramin, a HPSE-1 antagonist, to inhibit the activity of Ad-S/hep infected 
cells (Figure 2.4).  This suggests that 1) the increased activity (Figure 2.4A) and retention time  
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Figure 2.3. HPSE-1 activity increases with Ad-S/hep treatment in 70W cells compared to 
mock-treated cells.  Cells were infected with Ad-S/hep, Ad-AS/ hep, or none, and analyzed for 
HPSE-1 activity after 48 hours.  Equal amounts (100 µg) of cell lysates were incubated with 
FITC-HS for 18 hours (see Experimental Procedures section) and run on HPLC to analyze 
HPSE-1 activity. (A) Percentage of HS digested with different treatments. (B) Retention times 
calculated with different treatments.  Bars represent the mean with standard deviation of 
triplicate determinations. 
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Table 2.1. Modulation of HPSE-1 activity with Ad-S/hep or Ad-AS/hep 
treatment  
 
Treatment 
(MOI) 
A450 (nm)* 
  
pAd5-Blue 0.65 ± 0.05 
Ad-S/hep 0.21 ± 0.03 
Ad-AS/hep 0.73 ± 0.06 
  
 
* The higher the OD value, the lower is the HPSE-1 activity. The A450 starting point of no 
enzyme degradation was 0.79. 
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Table 2.2.  HPSE-1 activity decreases with Ad-AS/hep treatment in a  
dose-dependent manner 
 
Cell line Treatment (MOI) A450 (nm)* 
 pAd5-Blue Ad-S/hep Ad-AS/hep 
 
 
B16B15b 
            -              -             - 
             1.1  ± 0.19 
             1.0  ± 0.14 
             0.87 ± 0.01 
             0.92 ± 0.03 
             1.2   ± 0.10 
           125              -             - 
           100             25             - 
           50             25             50 
           -             25             100 
    
    
 
 70W 
            -             -             - 
             0.90 ± 0.33 
             0.83 ± 0.04 
             0.59 ± 0.01 
             0.72 ± 0.02 
             0.87 ± 0.16 
           125             -             - 
           100             25             - 
           50             25             50 
           -             25             100 
 
 
* The higher the OD value, the lower is the HPSE-1 activity. The A450 starting point of no 
enzyme degradation was 1.7. 
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Figure 2.4.  HPSE-1 activity is inhibited by suramin in Ad-S/hep – treated 70W cells. Cells 
were infected with Ad-S/hep or pAd5-Blue as control and analyzed for HPSE-1 activity after 48 
hours. Equal amounts of cell lysates were incubated with FITC-HS for 18 hours with or without 
suramin (500 µM) and run on HPLC to analyze HPSE-1 activity. (A) The percentage of HS 
digested with different treatments. (B) Retention times calculated with different treatments.  Bars 
represent the mean with standard deviation of triplicate determinations. 
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(Figure 2.4B) in the assay is due to an up-regulation of HPSE-1 in the Ad-S/hep - infected cells, 
and 2) this activity can be further modulated by suramin (500 µM) as an HPSE-1 inhibitor 
(Figure 2.4). 
Inhibition of HPSE-1-Induced Invasion by Ad-AS/hep Infection of Melanoma Cells 
To investigate HPSE-1 mechanisms in metastatic cell invasion, chemoinvasion assays 
were performed using MatrigelTM- coated Transwell chamber systems.  B16B15b and 70W cells 
when infected with Ad-S/hep, possessed augmented invasive properties compared with pAd5-
Blue-infected cells, while Ad-AS/hep - treated cells showed a significant inhibition of invasion 
(Figure 2.5).  These results suggest that the antisense adenoviral construct selectively inhibited 
HPSE-1 - induced invasive properties in B16B15b and 70W cells. 
Inhibition of Tumor Formation with Ad-AS/hep - Treated 70w Cells 
To evaluate HPSE-1 mechanism in metastatic cell invasion, human malignant melanoma 
70W cells were infected with Ad-S/hep, Ad-AS/hep or pAd5-Blue vectors and injected in 6-
weeks old female athymic nude (nu/nu) mice.  Mice injected with pAd5-Blue and Ad-S/hep - 
treated 70W cells developed tumors but none of the Ad-AS/hep - treated cells were capable of 
extensive tumor formation (Figure 2.6, Table 2.3).  During quantitation of tumor formation, we 
found microscopic tumors in one of the mice treated with Ad-AS/hep suggesting that the 
antisense adenoviral construct selectively inhibited HPSE-1-induced invasive properties in 70W 
cells.  Because control cells already expressed relatively high levels of HPSE-1, we were unable 
to see a significant difference between our control and Ad-S/hep groups; however, we found a 
significant difference between the control and the Ad-AS/hep groups.  Furthermore, formalin-
fixed tissues from each group were analyzed for immunohistochemistry (Figure 2.7): lung tumor 
tissue from the Ad-S/hep group expressed HPSE-1 more consistently and with an increased  
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Figure 2.5.  Ad-AS/hep treatment inhibits HPSE-1–mediated invasion of melanoma cells. 
Metastatic melanoma cells (B16B15b and 70W) infected with pAd5-Blue, Ad-S/hep, or Ad-
AS/hep were placed in invasion chambers (12 µm diameter pore size) for 72 hours at 370C in a 
humidified 5% CO2/95% air (vol/vol) atmosphere. Noninvasive cells were wiped from the upper 
chamber with a cotton swab and invasive cells were detected with the Diff-Quick Stain Kit. Bars 
represent the mean with standard deviation of triplicate determinations (*P < 0.01, **P < 0.1). 
Student’s t test was used as statistical method. 
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Figure 2.6.  Ad-AS/hep treatment inhibits tumor formation in athymic nude (nu/nu) mice.  
Human malignant melanoma 70W cells were infected with pAd5-Blue control vector (A), Ad-
S/hep (B), or Ad-AS/hep (C) and were injected intravenously in 6-week – old female athymic 
nu/nu mice.  At the end of the experimental period, mice were euthanized and examined for 
tumor formation.  Quantification of lung tumor formation and statistical analyses were 
performed on the number of experimental animals and shown in Table 2.3. 
 
Table  2.3 - Ad-AS/hep treatment inhibits tumor formation in  
nude (nu/nu) mice 
 
Treatment Number of Lung Tumor Nodules Lung Weight 
(mg, mean ± SD) Median Range 
    
pAd5-Blue 16 0-32a 571 ± 154 
Ad-S/hep 12 0-44b 453 ± 210 
Ad-AS/hep 0 0-4c 366 ± 75 
    
 
a: Eighty percent of mice had lung tumors.  b: Eighty percent of mice had lung tumors.  c: 
Twenty percent of mice had lung tumors (p = 0.04).  Student’s t test was used as statistical 
method. 
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Figure 2.7.  Ad-S/hep/Ad-AS/hep–mediated HPSE-1 expression in nude (nu/nu) mice. 
Animals were injected with pAd5-Blue – , Ad-S/hep – , or Ad-AS/hep – infected 70W cells and 
formalin-fixed lung tumor tissues were analyzed by immunohistochemistry.  Intense staining of 
HPSE-1 was found in lung tissues of animals treated with Ad-S/hep – infected 70W cells (C and 
D) compared to pAd5-Blue (A and B) or Ad-AS/hep (E and F) treatment. HPSE-1 staining 
observed in the Ad-AS/hep is due to the presence of the enzyme in the endothelium and 
macrophages in lung tissues. Digital images were produced on an Axioplan microscope with 
advanced spot imaging program at x10 (A, C, and E) and x40 (B, D, and F) objectives using 
identical conditions for all photographs and antibodies used; x40 objectives show the different 
intensities of HPSE-1 staining by various treatments. 
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immunohistochemical intensity than in the control group.  HPSE-1 staining was also observed in 
the Ad-AS/hep group but mainly due to presence of the enzyme in the endothelium (Marchetti 
1997) and macrophages (Sasaki, Higashi et al. 2004) of lung tissues (Figure 2.7). 
DISCUSSION 
 
Invasion and metastasis are characteristic features of malignant tumors and are among the 
greatest impediments to curing cancer.   Inhibition of tumor invasion is an attractive approach for 
the treatment of highly malignant tumors (Zetter 1998; Folkman 2001).   Substantial evidence 
accumulated over the last three decades indicates that HSPG act to inhibit invasion by promoting 
tight cell–cell and cell–ECM interactions (Bernfield, Gotte et al. 1999; Iozzo 2001; Sanderson 
2001).   Degradation of HS weakens cell–cell and cell–matrix adhesion in melanoma and other 
tumor cells (Dhodapkar, Kelly et al. 1997; Ma and Geng 2000; Engbring, Hoffman et al. 2002).   
HSPG can also act both as reservoirs of growth factors (Iozzo, Cohen et al. 1994; Vlodavsky and 
Friedmann 2001) and as coreceptors for ligand binding and subsequent intracellular signaling.   
These heparin-binding factors are involved in growth, invasion, angiogenesis, and tumor 
progression (Bernfield, Gotte et al. 1999; Iozzo and San Antonio 2001; Vlodavsky, Goldshmidt 
et al. 2001).   HS-degradative enzymes, such as heparitinases, heparinases from Flavobacterium 
heparinum, or endoglucosaminidases, cleave HS to disaccharides and tetrasaccharides, which are 
too short for growth factor and ECM ligand binding (Ernst, Langer et al. 1995; Ernst, 
Venkataraman et al. 1996; Liu, Shriver et al. 2002).  However, HPSE-1 is an endo-β-D-
glucuronidase that cleaves HS at specific intrachain sites, resulting in fragments of appreciable 
size (10–20 sugar units) (Nakajima, Irimura et al. 1984; Nakajima, Irimura et al. 1988; Marchetti 
1997; Vlodavsky, Goldshmidt et al. 2001).  This confirms the notion that HPSE-1, in degrading 
HSPG and releasing HS-bound angiogenic/growth factors, may aid the modulation of growth 
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factor activities in metastasis (Marchetti, Denkins et al. 2003; Reiland, Sanderson et al. 2004).  
Thus, HPSE-1 is an attractive target for the development of novel antimetastatic drugs because 
of the considerable evidence implicating this enzyme in tumor cell invasion (Vlodavsky and 
Goldshmidt 2001).   
In the present study, we have demonstrated that overexpression of human HPSE-1 
enhanced tumor cell invasiveness in vitro and in vivo, and that this invasive ability was 
significantly reduced by inhibiting HPSE-1 expression using an adenovirus-mediated antisense 
gene delivery strategy.   HPSE-1 expressions, as well as its biologic activity, were enhanced in 
metastatic melanoma cell lines following Ad-S/hep treatment.  Conversely, treatment with Ad-
AS/hep resulted in decreased HPSE-1 expression as well as cell invasiveness in vitro and in vivo.  
For example, in our experiments designed to analyze the effects of Ad-S/hep, we found that there 
was an upregulation of protein expression in both B16B15b and 70W melanoma cell lines.  
Conversely, we observed the opposite using Ad-AS/hep (Figure 2.2).  The reduction in HPSE-1 
protein level was consistent over multiple experiments.  The inability to completely inhibit 
HPSE-1 protein expression was possibly due to slow protein turnover rate.  However, the 
reduction results in significant biologic effects in in vitro invasion assays or in in vivo 
tumorigenic assays, despite this small change in the protein level. 
HPSE-1 activity was inhibited in a dose-dependent manner when cells were coinfected 
with Ad-S/hep and different doses of Ad-AS/hep (Table 2.2).  Furthermore, we detected an 
increase in HPSE-1 activity with Ad-S/hep infection (Figure 2.3, Table 2.1).  There was a small 
reduction of activity with Ad-AS/hep treatment compared to mock-treated cells (Figure 2.3A), 
which significantly decreased when HPLC retention times were calculated from these 
experiments (P = .02) (Figure 2.3B).   
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We were also able to inhibit the increased activity of Ad-S/hep with suramin, a known 
HPSE-1 inhibitor, therefore relating this augmented cell invasiveness to HPSE-1 (Figure 2.4).   
The poor sensitivity of HPSE-1 activity assays may reflect a lack of sensitivity at low HPSE-1 
levels.  Alternatively, differences between HPSE-1 activity and biologic assays can be due to 
lysis of the cells (HPSE-1 activity assays) versus using intact cells in in vitro (invasion assays) 
and in vivo (tumorigenic assays) analyses.  In fact, we observed both a significant biologic effect 
in chemoinvasion assays and a reduction in both B16B15b and 70W cell-invasive properties 
(Figure 2.5).  Of equal importance, mice injected with pAd5-Blue– and Ad-S/hep–treated 70W 
cells showed extensive tumor formation, whereas none of the mice injected with Ad-AS/hep–
treated 70W cells presented any evidence of macroscopic malignancy (Figure 2.6, Table 2.3).  
Because control cells already expressed high levels of HPSE-1, we were unable to detect a 
significant difference between control and Ad-S/hep groups; however, this was found between 
the control and Ad-AS/hep groups (P = .04).  Secondly, immunohistochemical analyses on the 
animal tissue from each group revealed more consistent and intense HPSE-1 staining in Ad-
S/hep–infected cells (Figure 2.7, C and D) compared to using pAd5-Blue (Figure 2.7, A and B) 
or Ad-AS/hep vectors (Figure 2.7, E and F ).  These findings indicate that even a small reduction 
in HPSE-1 activity can lead to a great difference in its biologic function and may also suggest 
that the antisense-mediated gene delivery strategy can be a very effective way in preventing 
tumor formation and its metastatic potential. 
Many chemotherapeutic agents are available to target HPSE-1 to suppress metastasis 
(Miao, Elkin et al. 1999; Parish, Freeman et al. 1999; Dhar, Gullbo et al. 2000; Meyers, 
Gagliardi et al. 2000; Edovitsky, Elkin et al. 2004).  However, these agents have their limitations 
in affecting malignant cells as well as normal cells, thus affecting the normal growth and 
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functions of vital organs.  Secondly, delivering these agents to specific sites can be difficult.  
Finally, interactions between the antimetastatic agents and biologic molecules like HSPG can 
interfere with normal biologic processes.  Accordingly, to specifically inhibit the metastatic 
potential, which is a frequent malignant phenotype of many tumor types, a more specific 
therapeutic approach, such as the antisense-mediated RNA expression, needs to be considered.  
Antisense RNA can bind to the mRNA expressing the gene of interest and can block protein 
expression by the target cells. 
Several groups have reported that tumor cells transfected with HPSE-1 cDNA acquire a 
highly metastatic phenotype in vivo (Vlodavsky, Friedmann et al. 1999) (reviewed in Ref.  
(Vlodavsky and Goldshmidt 2001)).  Conversely, inhibition of HPSE-1 by means of antisense 
strategy, antimetastatic drugs, or gene silencing has resulted in decreased invasiveness in vitro 
(Zhang, Fu et al. 2003) and in vivo (Uno, Fujiwara et al. 2001; Edovitsky, Elkin et al. 2004).  
However, in other antisense animal models, tumor cells treated with viral vectors were directly 
injected into the thoracic cavity (Uno, Fujiwara et al. 2001), which bypasses several steps in the 
metastatic process that includes adhesion to endothelium and invasion (Parish, Coombe et al. 
1987; Nakajima, Irimura et al. 1988; Vlodavsky, Bar-Shavit et al. 1991; Hulett, Freeman et al. 
1999; Kussie, Hulmes et al. 1999; Toyoshima and Nakajima 1999; Vlodavsky, Friedmann et al. 
1999; Vlodavsky and Friedmann 2001; Zetser, Bashenko et al. 2003; Sasaki, Higashi et al. 
2004).   A recent report of HPSE-1 inhibition by siRNA strategy also demonstrated reduced 
tumor load and increased survival in animals (Edovitsky, Elkin et al. 2004).  Consistent with 
these findings, we have observed a significant inhibition of tumor formation in in vivo 
experiments where HPSE-1 – expressing 70W cells were infected with Ad-AS/hep and 
subsequently injected in athymic nu/nu mice (Figure 2.6, Table 2.3).  This suggests that Ad-
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AS/hep has the potential to suppress the metastatic phenotype of highly invasive tumor cells.  
Thus, approaches that selectively block the expression of molecules implicated in cellular 
invasion may be clinically more efficacious in preventing tumor cell dissemination than the ones 
used to induce tumor cell apoptosis.   
The metastatic phenotype is considered decisive for tumor progression and several key 
molecules involved in these complex biologic events are potential candidates for therapeutic 
intervention.   Our findings suggest that HPSE-1 is an attractive target for therapy and that its 
expression can be modified by adenoviral vectors to achieve favorable outcome in cancer 
metastasis. 
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CHAPTER III 
OVEREXPRESSION OF HEPARANASE INHIBITS BRAIN-
METASTASIS IN VIVO  
INTRODUCTION 
Heparanase (HPSE) is an endo-β-D-glucuronidase that cleaves the heparan sulfate chains 
(HS) on heparan sulfate proteoglycans (HSPG) and thus contributes in extracellular matrix 
(ECM) degradation and remodeling.  Conventionally, HPSE activity is associated with the 
metastatic potential of a variety of tumor-derived cell types (Vlodavsky and Friedmann 2001).  
HPSE protein expression was found to be up-regulated in various primary human tumors 
compared to surrounding non-cancerous tissues including hepatocellular (El-Assal, Yamanoi et 
al. 2001) and gastric carcinomas (Tang, Nakamura et al. 2002), bladder (Gohji, Okamoto et al. 
2001), breast (Maxhimer, Quiros et al. 2002), and colon (Friedmann, Vlodavsky et al. 2000) 
cancers, pancreatic adenocarcinoma (Koliopanos, Friess et al. 2001; Kim, Xu et al. 2002; 
Rohloff, Zinke et al. 2002) and malignant melanoma (Murry, Greiter-Wilke et al. 2005).  Over-
expression of HPSE in lymphoma (Goldshmidt, Zcharia et al. 2002) or melanoma cells (Roy, 
Reiland et al. 2005) has been shown to enhance tumor metastasis and angiogenesis.  Similarly, 
inhibition of HPSE expression with antisense or siRNA resulted in a significant decrease in 
melanoma metastatic phenotype (Edovitsky, Elkin et al. 2004; Roy, Reiland et al. 2005).   
HPSE also facilitates cell invasion associated with autoimmune diseases, inflammation, 
and angiogenesis (El-Assal, Yamanoi et al. 2001; Elkin, Ilan et al. 2001; Gohji, Okamoto et al. 
2001; Goldshmidt, Zcharia et al. 2002), possibly by releasing HS-bound angiogenic growth 
factors thereby activating these molecules.  Accumulating evidence, including available clinical 
data, suggests that HPSE is an important molecular determinant in the progression of various 
primary and metastatic human tumors.  However, an effect of HPSE overexpression or down 
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regulation in metastatic brain tumor has not been investigated so far.  Based on the available 
basic research and clinical data, we hypothesized that HPSE overexpression in brain-metastatic 
melanoma would accelerate brain-tumor development, and inhibition of HPSE would have the 
opposite effect.   
To explore this hypothesis, we used adenoviral vectors expressing the full-length human 
hpse gene in the sense (Ad-S/hep) or the antisense (Ad-AS/hep) orientations to specifically 
upregulate or inhibit HPSE protein expression.  We were able to upregulate HPSE protein 
expression, activity, and in vitro invasive properties of the brain-metastatic melanoma cells 
(70W) by infecting the cells with Ad-S/hep and the opposite effects were observed with Ad-
AS/hep in our previous report (Roy, Reiland et al. 2005).  We were also able to demonstrate an 
inhibition of lung-metastasis formation by infecting the cells with the Ad-AS/hep in vivo 
whereas there was no significant difference in lung metastasis formation in the animals that were 
injected with cells that were either infected with the control (pAd5-Blue) or the Ad-S/hep vectors 
(Roy, Reiland et al. 2005).   
However, in the previous study, we did not observe any brain-metastasis.  Therefore, in 
the present report, we repeated the animal experiment, and to bypass the lungs, we injected the 
cells (70W) following various viral vector treatments, into the internal carotid artery of athymic 
nude (nu/nu) mice.  As expected, at the end of the in vivo experiment, there was a complete 
inhibition of brain-tumor formation in all animals in the Ad-AS/hep group.  We observed brain-
tumor formation in both the control and the Ad-S/hep groups.  Unexpectedly, animals in the Ad-
S/hep group developed smaller and fewer tumors than the control group.  Furthermore, some of 
the animals in the Ad-S/hep group did not have any brain tumors.  We confirmed that the Ad-
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S/hep was indeed overexpressing HPSE by using a HPSE activity assay with the pooled tumor 
tissue from animals. 
MATERIALS AND METHODS 
Materials   
Heparan sulfate (HS) from bovine kidney was acquired from Sigma Chemical Company 
(St.  Louis, MO).  DMEM and Ham’s F-12 nutrient medium and trypsin-EDTA were purchased 
from Gibco (Grand Island, New York, NY), and FBS from Hyclone Laboratories (Logan, UT).  
All other chemicals used were reagent grade or better.   
Cells and Tissue Culture Conditions 
Early-passage melanoma cells with metastatic abilities of human origin (70W line) 
(Ishikawa, Dennis et al. 1988; Ishikawa, Fernandez et al. 1988) were maintained as monolayer 
cultures in a 1:1 (v/v) mixture of DMEM/F-12 supplemented with 10% (v/v) FBS.  Cells were 
maintained at 37°C in a humidified 5% CO2/95% air (v/v) atmosphere and passaged using 
trypsin-EDTA (70W) before reaching confluence.  The transformed embryonic kidney cell line 
293 was grown in DMEM/F-12, supplemented with 10% FBS and penicillin (100 units/ml), and 
streptomycin (100 µg/ml).  The 293 cells were used for the production of adenoviral vectors 
(Roy, Reiland et al. 2005). 
Construction of Recombinant Adenovirus Containing the Human Heparanase Gene 
An adenovirus expression vector kit (Takara Biomedicals Inc., Tokyo, Japan) was used to 
generate recombinant adenovirus for the expression of human HPSE gene in both sense and 
antisense orientations.  Replication-deficient, E1- and E3-deleted recombinant adenovirus 
serotype 5 (Ad5) was used as the viral backbone.   Plasmid DNA containing the cloned hpse 
gene and synthetic oligonucleotides Hep-5’ (complementary to the 5’ end of the gene) and Hep-
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3’ (complementary to the 3’ end of the gene) were used to produce PCR products encompassing 
the hpse sequence (1632 bp).  PCR products were treated with T4 DNA polymerase to generate 
uniformed blunt ends required for the ligation reaction into pAxCAwt cosmid provided by the 
Takara kit.  After cloning the hpse gene into cosmid vector, availability of the recombinant 
cosmids containing the target gene in sense (5’ - 3’ under the CAG promoter of the vector) and 
antisense (3’ - 5’) orientations were confirmed by restriction analysis.  Cosmid DNAs were 
produced in large quantities and after gradient purification were used for cotransfection with 
adenovirus genomic DNA-terminal protein complex (DNA-TPC provided by the kit) into 293 
cells.  Following the kit protocol, recombinant adenoviruses expressing human hpse in both 
sense (Ad-S/hep) and antisense (Ad-AS/hep) orientations were generated.  Integrity of these 
recombinant viruses was confirmed by PCR and restriction analysis.  The E1-, E3-deleted, 
replication deficient adenovirus pAd5-Blue was used as the control vector.  Viral titer was 
quantified by determination of the 50% infectivity on tissue culture (TCID 50) in 293 cells (Roy, 
Reiland et al. 2005). 
Adenoviral Infection  
70W cells were plated on 100 mm dishes (106 cells/dish).  Twenty four hours later, cells 
were washed twice with PBS containing 2 mM EDTA, and infected with virus diluted in serum-
free DMEM/F-12.  To maximize cell viability and protein expression, cells were infected with 
the viral vectors at a multiplicity of infection (M.O.I.) of 50.  Plates were then incubated at 37°C 
for 1 hr, rocking gently every 10 min.  Infection was terminated by adding culture medium 
containing penicillin (100 units/ml) and streptomycin (100 µg/ml).  Cells were then incubated at 
37oC for an appropriate period of time.  Immunofluorescent control experiments were performed 
to confirm cell infectivity of the adenoviral vectors (Roy, Reiland et al. 2005). 
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Heparanase Activity Assays   
HPSE activity was determined by degradation of FITC-HS using high-speed gel 
permeation column chromatography (HPLC) as previously described (Toyoshima and Nakajima 
1999; Roy, Reiland et al. 2005).  Briefly, homogenized tumor tissues (100 and 200 µg lysate/µg 
of HS) were prepared and incubated with FITC-HS at 37oC for 18 hr in 100 µl of sodium acetate 
(100 mM, pH 4.2).  Reaction was terminated by heating samples for 100oC for 15 min.  HS 
products yielded by HPSE reaction were analyzed by size exclusion chromatography performed 
on a HP1090 liquid chromatograph with a photodiode array detector (Agilent Technologies Inc., 
Wilmington, DE) and a HP1046 programmable fluorescence detector (Agilent Technologies 
Inc., Wilmington, DE).  Samples (25 µl) were injected on a TSK-GEL 3000SWXL column (5 µm, 
7.8 mm x 30 cm) with a TSK-GEL SWXL guard column (5 µm, 6.0 mm x 4.0 cm) from Tosoh 
Bioscience (Montgomeryville, PA) at an ambient temperature (25oC).  Samples were 
isocratically eluted using Tris-HCl (25 mM), NaCl (150 mM), pH 7.5 at a flow rate of 0.5 
ml/min with a sample splitter placed between the column and detectors to maintain a column 
pressure of less than 70 bar.  Fluorescence was monitored with excitation at 490 nm and 
emission at 520 nm, then data was processed and peaks were integrated using HP ChemStation 
software (Agilent Technologies Inc., Wilmington, DE).  HPSE activity was determined by 
measuring the decrease in fluorescence intensity in the first one-half area of the intact FITC-HS 
peak chromatogram.  The retention times were calculated from the highest peak of the 
chromatograms. 
In Vivo Tumorigenic Assays 
Human malignant melanoma 70W cells were infected with Ad-S/hep, Ad-AS/hep and 
control pAd5-Blue at a M.O.I. of 50.  Cells were harvested 24 hr after infection, and resuspended 
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in DMEM/F-12 at a density of 2.5 x 106 cells/ml.  Female athymic nu/nu mice six-weeks old (n= 
10 per group) were injected with 200 µl of cell suspension (5 x 105 cells) through a 31-gauge 
needle in the internal carotid artery (Schackert and Fidler 1988).  Briefly, the mice were 
anesthetized with isoflurane, placed on a dissecting table with a heating pad on their backs, and 
examined under a dissecting microscope.  The hair over the trachea was shaved and the neck was 
prepared for surgery with alcohol-iodine.  The skin was cut by a median incision.  After 
dissection, the trachea was exposed.  The muscles were separated to expose the carotid artery, 
which was then separated from the vagus nerve.  The artery was prepared for injection at a point 
proximal to the point of the division into the internal and external carotid arteries.  A clamp was 
placed proximal to the site of injection and the cells (70W) were injected slowly with a 31 gauge 
needle.  The injection site was glued with superglue and the clamp was removed.  The skin flaps 
were apposed and stapled.  At the end of two months, mice were euthanized and examined for 
tumor formation as previously described (Ishikawa, Fernandez et al. 1988).  Metastatic behavior 
per animal group (number of brain tumor nodules and brains wet weight) was then determined.   
RESULTS 
Inhibition of Brain-Tumor Formation in Ad-S/hep - and Ad-AS/hep - Treated 70W Cells 
 
To evaluate HPSE mechanism in metastatic cell invasion, human malignant melanoma 
70W cells were infected with Ad-S/hep, Ad-AS/hep or pAd5-Blue vectors and injected in 6-
weeks old female athymic nude (nu/nu) mice.  Mice injected with pAd5-Blue and Ad-S/hep - 
treated 70W cells developed tumors but animals in the Ad-S/hep - treated cells had smaller and 
fewer tumor formation (Figure 3.1, Table 3.1).  In addition, while all the animals in the pAd5-
Blue group developed tumors (10/10), only 66% of the animals in the Ad-S/hep had tumors (6/9, 
we lost one animal following the procedure).  As with our previous report, Ad-AS/hep inhibited  
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Figure 3.1.  Overexpression of HPSE inhibits brain-tumor formation in athymic nude 
(nu/nu) mice.  Human malignant melanoma 70W cells were infected with pAd5-Blue control 
vector (A), Ad-S/hep (B), or Ad-AS/hep (C) and were injected intracarotid in 6-week – old 
female athymic nu/nu mice.  At the end of the experimental period, mice were euthanized and 
examined for tumor formation (black spots).  Quantification of brain tumor formation and 
statistical analyses were performed on the number of experimental animals and are shown in 
Table 3.1. 
 
Table 3.1 - Overexpression of HPSE inhibits tumor formation in 
nude (nu/nu) mice 
 
Treatment Number of Brain Tumor Nodules Brain Weight 
(mg, mean ± SD) 
Median Range 
    
pAd5-Blue 6 1-14a 422 ± 13 
Ad-S/hep 2 0-8b*   432 ± 26 
Ad-AS/hep 0 0c**     430 ± 16 
    
 
a: 100% of mice had brain tumors.  b: 66% of mice had brain tumors;  c: none had 
brain tumors (*: p < 0.01, **: p < 0.0003 compared to control).  Student’s t test was used as 
statistical method. 
B C A 
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tumor formation in all of the mice treated with Ad-AS/hep (0/10) suggesting that the antisense 
adenoviral construct selectively inhibited HPSE-induced metastatic properties in 70W cells.   
Heparanase Activity is Upregulated in Ad-S/hep–Treated Brain Tumor Tissue 
To confirm that the Ad-S/hep was indeed overexpressing HPSE in the brain-tumors, we 
next performed the HPSE activity assay with pooled brain and tumor tissue from animals from 
each group.  We used a specific HPSE activity assay on fluorescein isothiocyanate (FITC)-
labeled HS in 70W cells.  This assay detects HPLC profile shifts based on the size of HS 
fragments (Toyoshima and Nakajima 1999; Reiland, Sanderson et al. 2004; Roy, Reiland et al. 
2005).  Since HPSE cleaves the HS chains into discrete fragments, we detected a shift in the 
profile when compared to FITC-HS alone which was used as negative control (Toyoshima and 
Nakajima 1999; Reiland, Sanderson et al. 2004; Roy, Reiland et al. 2005) (data not shown).  We 
observed a decrease in fragment size in Ad-S/hep-treated tumor tissue compared to pAd5-Blue 
treatment, which indicated increased HPSE activity in the Ad-S/hep group (Figure. 3.2).  HPSE 
activity was increased by three fold in the Ad-S/hep group compared to pAd5-Blue by 
calculating percent of HS digestion (Figures 3.2A and B).  We also observed HPSE activity in 
the brain tissue of Ad-AS/hep treatment group.   
A prominent difference in the HPLC retention times was seen between the Ad-S/hep and 
the control.  These retention times reflect differences in the size of the predominant HS 
fragments (Toyoshima and Nakajima 1999; Reiland, Sanderson et al. 2004; Roy, Reiland et al. 
2005).  The brain-tumor tissue in the Ad-S/hep group showed a higher retention time compared 
to Ad-AS/hep and pAd5-Blue treatment groups suggesting that increased digestion of HS chains 
resulted from an enhanced HPSE activity (Figures 3.2C and D). 
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Figure 3.2.  HPSE activity is upregulated in brain tumor tissue of animals in Ad-S/hep 
treatment group compared to pAd5-Blue.  Tumor tissue with surrounding normal brain tissue 
(pAd5-Blue and Ad-S/hep), or normal brain (Ad-AS/ hep) were analyzed for HPSE activity.  
Equal amounts [100µg (A and C) and 200 µg (B and D)] of tissue were incubated with FITC-HS 
for 18 hours (see Experimental Procedures section) and run on HPLC to demonstrate HPSE 
activity. (A and B) Percentage of HS digested with different treatments. (C and D) Retention 
times calculated with different treatments. 
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DISCUSSION  
Over the past two decades, HPSE activity has been associated with the metastatic potential 
of various tumor derived cell lines and in both primary and secondary tumor development.  
Prometastatic properties of HPSE are attributed mainly to its involvement in ECM remodeling 
and liberation of various HS-bound growth factors (Nakajima, Irimura et al. 1983; Vlodavsky, 
Fuks et al. 1983; Nakajima, Irimura et al. 1986; Ricoveri and Cappelletti 1986; Nakajima, 
Irimura et al. 1988).  The cloning of a single human heparanase cDNA sequence reported by 
several groups independently (Hulett, Freeman et al. 1999; Kussie, Hulmes et al. 1999; 
Toyoshima and Nakajima 1999; Vlodavsky, Friedmann et al. 1999) suggested that mammalian 
cells express only one dominant HS-degrading enzyme.  This is in contrast to the large number 
of proteases that are capable of degrading and remodeling the variety of polypeptides present in 
the ECM (Werb 1997; Sanderson R.D. 2005) and emphasizes the biological importance of this 
glycosidase.  A number of studies have now presented evidence that HPSE overexpression in 
tumor cells enhances tumor growth and angiogenesis (Uno, Fujiwara et al. 2001; Vlodavsky, 
Goldshmidt et al. 2002; Sanderson, Yang et al. 2004; Roy, Reiland et al. 2005).   
Surprisingly, in our study using the brain-metastatic melanoma cells, overexpression of 
HPSE led to inhibition of tumor formation.  We confirmed that the Ad-S/hep was indeed 
overexpressing HPSE in the brain-tumors with a HPSE activity assay.  HPSE activity was 
increased by three fold in the Ad-S/hep group compared to pAd5-Blue by calculating percent of 
HS digestion (Figures 3.2A and B).  We also observed HPSE activity in the brain tissue of Ad-
AS/hep treatment group.  The low levels of HPSE activity in the Ad-AS/hep group was possibly 
due to HPSE expressed by the endothelial cells and the astrocytes (Marchetti 1997; Marchetti, Li 
et al. 2000), since there were no detectable tumors in the brains of these animals (Figures 3.2A 
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and B).  This is in agreement with the recent report by Zetser et al. (2003) using a glioma model.  
In that report, moderate levels of HPSE stimulated tumor growth and invasion, whereas higher 
levels produced the opposite effect and inhibited tumor development, indicating a concentration-
dependence for its activity (Zetser, Bashenko et al. 2003).   
This unexpected finding of inhibition of tumor formation led us to hypothesize that 
extensive remodeling of the ECM and cell-surface HS by higher concentrations of HPSE 
disrupted the growth factor-mediated activity in the brain-metastatic melanoma cells, since much 
of the pro-metastatic and the pro-angiogenic activities of HPSE are primarily due to modification 
of the HS-bound growth factor activities (Reiland, Kempf et al. 2006).  This possibility has been 
investigated by treating the human brain-metastatic melanoma (70W) cells with various 
concentrations of HPSE and exploring its effect on fibroblast growth factor-2 (FGF2)-mediated 
signaling and activity (Reiland, Kempf et al. 2006).  FGF2 was chosen because it is an important 
mediator of melanoma angiogenesis and progression (Herlyn 2005).  Furthermore, HS sequence 
and length affect FGF2 activity, and binding to HS by both FGF2 and FGF receptors (FGFR) is 
essential for its signaling and subsequent pro tumorigenic activities (Rapraeger 1995).  HPSE at 
low concentrations enhanced FGF2 binding and FGF2-mediated signaling and angiogenesis, 
whereas the opposite effects were observed with supraphysiological concentrations of HPSE 
(Reiland, Kempf et al. 2006).  That study demonstrating HPSE’s ability to both augment and 
inhibit FGF2 binding, signaling and FGF2-mediated angiogenesis in a concentration-dependent 
manner could explain the unexpected tumor inhibitory phenomenon by high levels of HPSE 
(Reiland, Kempf et al. 2006).   
Extensive remodeling of cell surface HS may hinder growth factor binding and 
internalization (Iozzo 2001; Sanderson 2001).  However, a modest degradation of cell surface 
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HS by low levels of HPSE, which more closely resembles in vivo expression levels, possibly 
alters the HS structure resulting in either decreased or increased interactions with different 
growth factors.  Furthermore, HPSE degradation of HS could change the availability of HS-
bound growth factors in the tumor microenvironment by liberating them from the ECM and the 
cell surface.   
In the report by Zetser et al. (2003) in the glioma model, the inhibitory effect of high 
HPSE expression on tumor growth was due to a decrease in cell proliferation.  HPSE also 
increased adhesive properties in the cells at both low and high concentrations by inducing β-1 
integrin expression which is associated with aggressive properties of tumor cells.  According to 
their study, while adhesion to vascular endothelial cells and subendothelial matrix was promoted 
by low levels of HPSE, a further increase in HPSE expression led to spreading of cells in tight 
monolayer that hindered metastasis formation (Zetser, Bashenko et al. 2003).   
Our work in brain-metastatic melanoma cells not only extends the concept that HPSE 
alters tumor responsiveness in multiple systems, but also suggests that these changes are due to 
HPSE-mediated HS remodeling of the tumor cell surface and the ECM (Reiland, Kempf et al. 
2006).  Interestingly, this inhibitory effect by high levels of HPSE has only been reported in the 
brain tumor models, indicating the possibility that there is a more complex regulation of this 
enzyme in the brain.   
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CHAPTER IV 
HEPARANASE-DEGRADED CELL-SURFACE HEPARAN SULFATE 
PROMOTES MELANOMA CELL MIGRATION AND ANGIOGENESIS 
 
INTRODUCTION 
 
Enzymatic remodeling of heparan sulfate proteoglycans (HSPG) within the tumor 
microenvironment is emerging as an important mechanism for dynamic regulation of tumor 
growth (Sanderson, Yang et al. 2004; Sanderson 2005).  HSPG are essential and integral 
components of the cell surface and extracellular matrix (ECM) that surrounds all mammalian 
cells.  This is a family of glycoproteins that is distinguished by the covalent attachment of one or 
more heparan sulfate glycosaminoglycan chains (HSGAG) to their protein core (Kjellen and 
Lindahl 1991).  In addition to providing structural integrity, they act as a storage depot for a 
variety of heparan sulfate (HS)-binding proteins, including growth factors and chemokines 
(Kjellen and Lindahl 1991).  HSGAG are directly involved with the angiogenic process by acting 
as co-receptors with angiogenic growth factors (Iozzo 2001).  As the interface between tumor 
cells and normal host cells, HSGAG mediate tumor and host cell interactions (Raman, 
Venkataraman et al. 2003).  HSGAG also influence tumor metastasis to sites such as the brain by 
arbitrating interactions between cancer cells, platelets, endothelial cells, and host organ cells 
(Varki and Varki 2002).  Intact HSGAG prevent metastasis by acting as a physical barrier in the 
ECM.  Heparanase (HPSE) secreted by tumor cells degrades HSGAG on the cell-surface and 
ECM, and thereby decreases the integrity of the barrier to malignant cell invasion (Vlodavsky 
and Friedmann 2001; Sanderson 2005). 
HPSE is an endo-β-D-glucuronidase that cleaves HS at specific intrachain sites, resulting 
in fragments of appreciable size (10–20 sugar units) (Nakajima, Irimura et al. 1984; Nakajima, 
Irimura et al. 1988; Marchetti 1997; Vlodavsky, Goldshmidt et al. 2001).  Various in vitro and in 
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vivo studies have suggested a role for HPSE in tumor invasion and metastasis (Hulett, Freeman 
et al. 1999; Vlodavsky, Friedmann et al. 1999; Koliopanos, Friess et al. 2001; Uno, Fujiwara et 
al. 2001; Goldshmidt, Zcharia et al. 2002; Kelly, Miao et al. 2003; Zetser, Bashenko et al. 2003; 
Roy, Reiland et al. 2005).  In addition, HPSE activity is upregulated in human cancers; namely, a 
number of descriptive studies on clinical samples demonstrated a correlation between tumor 
malignancy and HPSE levels (Nakajima, Irimura et al. 1988; Friedmann, Vlodavsky et al. 2000; 
Vlodavsky, Elkin et al. 2000; Koliopanos, Friess et al. 2001; Uno, Fujiwara et al. 2001; Kim, Xu 
et al. 2002; Maxhimer, Quiros et al. 2002; Tang, Nakamura et al. 2002; Kelly, Miao et al. 2003; 
Doweck, Kaplan-Cohen et al. 2006).   
In vivo animal studies also indicate that changes in the fine structure of tumor-cell-
surface insoluble HS or soluble HS in the ECM have profound effects on tumor-cell growth 
kinetics, angiogenesis and metastasis (Liu, Shriver et al. 2002a; Dai, Yang et al. 2005; Narita, 
Staub et al. 2006; Reiland, Kempf et al. 2006; Xu, Rao et al. 2007).  Depending on HS 
composition or sequences that are involved in the process of tumorigenesis, it can either act as 
pro-tumorigenic, or anti-tumorigenic agents (Liu, Shriver et al. 2002a; Reiland, Kempf et al. 
2006).  Soluble HS or HS in the ECM can also differentially regulate FGF-2 binding and 
signaling, leading to modification of angiogenesis of brain-metastatic melanoma cells depending 
on the HS concentration (Reiland, Kempf et al. 2006).   
Some of the HS-binding growth factors that are important for angiogenesis and tumor 
development are fibroblast growth factors (FGF1 and FGF2), vascular endothelial growth factor 
(VEGF), hepatocyte growth factor, transforming growth factor-β, and platelet-derived growth 
factor (Nurcombe, Smart et al. 2000; Sasisekharan and Venkataraman 2000; Iozzo 2001; 
Sasisekharan, Shriver et al. 2002; Sasaki, Higashi et al. 2004).  VEGF (Senger, Galli et al. 1983; 
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Senger, Perruzzi et al. 1986) was initially described as a highly specific mitogen for endothelial 
cells (Leung, Cachianes et al. 1989) and as a potent inducing agent for angiogenesis and 
vasculogenesis in a variety of physiological and pathological conditions (Plate, Breier et al. 
1992; Ferrara, Winer et al. 1993; Tuder, Flook et al. 1995; Ferrara and Davis-Smyth 1997).  
Inhibition of VEGF signaling by VEGF antagonists, antisense VEGF, or dominant negative 
VEGFR (VEGF receptor) impaired tumorigenesis in vivo (Kim, Li et al. 1993; Millauer, 
Shawver et al. 1994; Saleh, Stacker et al. 1996; Yano, Shinohara et al. 2000).  The VEGF family 
of proteins includes VEGF A through E and placenta growth factor (Neufeld, Cohen et al. 1996; 
Ranieri, Patruno et al. 2006).  VEGF A is the most studied and one of its splice variants, 
VEGF165, is the most potent and widely expressed isoform known (Plouet, Moro et al. 1997).  
VEGF165 is secreted as a disulfide-linked homodimer with two identical heparin-binding sites.  
HS, by binding to VEGF, regulates the diffusion, half-life, and affinity of VEGF165 for its 
cognate receptors (Gallagher 2001; Iozzo 2001). 
We sought to assess the role of HPSE-degraded cell-surface HSGAG in VEGF165 
signaling in brain-metastatic melanoma since VEGF is known to be essential for brain metastasis 
in melanoma (Yano, Shinohara et al. 2000).  We hypothesized that HPSE contributes to 
melanoma metastasis by generating bioactive HS from the cell-surface that stimulate biological 
activities associated with the metastatic cascade.  We demonstrated that the isolated cell-surface 
HSGAG stimulated migration but not proliferation of melanoma cells (B16B15b) in vitro, and 
that HSGAG also promoted angiogenesis in vivo, as assessed by the Matrigel™ plug assay.  
Interestingly, the melanoma cell-surface HSGAG did not stimulate murine brain endothelioma 
cell migration (b.End3) in vitro.  Finally, we attempted to characterize the isolated HS by ion-
pair HPLC.  Our results suggest that, in addition to remodeling the ECM and releasing growth 
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factors and chemokines, HPSE may contribute to the aggressive phenotypes of melanoma by 
releasing bioactive HS that might stimulate melanoma migration and angiogenesis independent 
of any growth factor or chemo/cytokine activity. 
EXPERIMENTAL PROCEDURES 
Materials 
Heparan sulfate (HS) from bovine kidney and heparin lyase II (heparinase II, no EC) 
derived from Flavobacterium heparinium were purchased from Sigma Chemical Company (St. 
Louis, MO).  Heparin-lyase I (heparinase, EC 4.2.2.7) and heparin lyase III (heparitinase, EC 
4.2.2.8) from Flavobacterium heparinium were obtained from Seikagaku (Seikagaku America, 
Falmouth, MA).  Heparin disaccharide standards were purchased from Sigma and Grampian 
Enzymes (Scotland, UK).  DMEM and Ham’s F-12 nutrient medium and trypsin-EDTA were 
purchased from Gibco (Grand Island, New York, NY), and FBS from Hyclone Laboratories 
(Logan, UT).  Reduced-growth factor MatrigelTM was obtained from BD Biosciences Discovery 
Labware (Bedford, MA).  All other chemicals used were reagent grade or better. 
Cells and Tissue Culture Conditions 
Early-passage melanoma cells with high metastatic abilities of murine (B16B15b line) 
(Marchetti 1997) origin were maintained as monolayer cultures in a 1:1 (v/v) mixture of 
Dulbecco's modified Eagle's medium/F-12 supplemented with 5% (v/v) fetal bovine serum.  
Murine brain endothelioma cells (b.End3) (Montesano, Pepper et al. 1990) were passaged in 
Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium 
bicarbonate and 4.5 g/L glucose supplemented with 10% fetal bovine serum.  Cells were 
maintained at 37°C in a humidified 5% CO2/95% air (v/v) atmosphere and passaged using 2 mM 
EDTA (B16B15b) or trypsin-EDTA (b.End3) before reaching confluence. 
 100
For enzymatic treatment with HPSE, cells were washed 3 times in DMEM/F-12 
containing 0.1% BSA, penicillin (100 U/ml) and streptomycin (100 µg/ml), then incubated with 
indicated concentrations (0-5 µg/ml) of recombinant HPSE in 50 mM HEPES-buffered 
DMEM/F-12 (pH 6.8) containing penicillin (100 U/ml) and streptomycin (100 µg/ml) for 18 h at 
37ºC in a shaker incubator at 50 rpm. 
HPSE Isolation and Activity   
Recombinant human HPSE was purified as previously described (McKenzie, Young et 
al. 2003; Reiland, Kempf et al. 2006).  Briefly, Sf9 insect cells, transfected with baculovirus 
transfer vectors containing HPSE subunits, were grown in SF900II serum-free medium (Gibco 
BRL, Grand Island, NY) for high-titer stocks.  Tni insect cells cultured in suspension using 
ExCell405 serum-free medium (JRH Bioscience, Lenexa, KS) were infected with high-titer stock 
for 48 h, and cells were subsequently removed by centrifugation. The supernatant was then tested 
for HPSE activity, filtered through a 0.45 µm filter, and loaded on a HiTrap heparin column 
(Amersham Biosciences, Piscataway, NJ).  The column was subsequently washed in TBS, then 
eluted using a 100 ml gradient of 0.15-1.0 M NaCl in 25 mM Tris-HCl (pH 7.5).  Collected 
fractions (1 ml) were screened for HPSE activity (Heparan Degrading Enzyme Assay Kit; 
Takara Mirus, Madison, WI) (Reiland, Sanderson et al. 2004).  HPSE eluted at 0.67 M NaCl, as 
expected (McKenzie, Young et al. 2003; Reiland, Kempf et al. 2006). 
Flow Cytometric Analyses 
Degradation of cell-surface HS was confirmed by flow cytometric analyses.  Briefly, 
B16B15b metastatic melanoma cells were treated with different concentrations of HPSE (0-5000 
ng/ml) overnight or Hep III (10 µg/ml) for 1 hour at 37oC on a shaker incubator.  The medium 
was removed at the end of the treatment and the cells were released by PBS-EDTA. Cells (1 x 
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106) were incubated with HS mAb 3G10 (Seikagaku) followed by incubations with super 
sensitive biotin-goat anti-mouse IgM (BioGenex, San Ramon, CA) and PE streptavidin 
(Molecular Probes, Eugene, OR) respectively.  Cells were then fixed in 200 µl cold 1% 
paraformaldehyde and stored at 4oC till analysis. Samples were analyzed for cell-surface 
HSGAG staining using FACScan Flowcytometer. Data were analyzed with WinMDI.  
Appropriate control samples were run to subtract background staining. 
Isolation of HSGAG from Cell-Surface 
B16B15b metastatic melanoma cells were treated with or without HPSE (5000 ng/ml) 
overnight at 37oC on a shaker incubator. Conditioned medium was collected and pH was 
adjusted to 6.0. The medium was then centrifuged at 5000 rpm for 10 minutes, filtered through 
0.22µm filters and boiled for 10 minutes. The medium was incubated with DEAE-Sephacel 
(Sigma) overnight and subsequently poured onto columns. HSGAG fragments bound to DEAE 
were washed with 0.1 M sodium phosphate and 0.15 M NaCl, pH 6.0, in the column. The 
fragments were gradient eluted with 0.5 M, 1.0 M, and 2.0 M NaCl in 0.1 M sodium phosphate 
buffer pH 6.0. The fragments were then concentrated and buffer-exchanged into ultra-pure water 
by application to a Centricon filter (Millipore Corporation, Bedford, MA). Finally, the isolated 
fragments were treated with pronase (Sigma) to remove protein contamination from isolated 
HSGAG. 
HPSE-degraded HSGAG used in biological experiments were analyzed by separating 
HSGAG on a Criterion 4-20% TBE gel (Bio-Rad Laboratories, Hercules, CA) for 20 min at 60 
mAmp.  Bands were visualized with alcian blue 8GX (Sigma-Aldrich) followed by silver 
staining (Pierce Endogen, Rockford, IL) (Pervin, Gallo et al. 1995).  Densitometric analyses 
were performed using a Versadoc imaging system (Bio-Rad Laboratories) to determine the 
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profile leading edge. Non-treated commercial HS from bovine kidney were simultaneously run at 
various concentrations to obtain quantitative analysis. 
Western Blotting Analyses 
For signal transduction studies, cells were plated in 12 or 24-well tissue culture wells for 24-
48 h to allow cell adhesion.  HPSE/Hep III treatments of cell surface HS were performed as 
described above.  Cells were exposed to 0-100 ng/ml of each of FGF2 or VEGF or HS in 
triplicates for 10-30 min at 37°C.  Where indicated, FGF2/VEGF were added together with 0-
100 ng/ml HS.  Following stimulation, the medium was aspirated from cells and 100-200 µl of 
lysis buffer [20 mM Tris-HCl (pH 7.4) containing 1% SDS, 1 mM PMSF, 0.1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride, 0.1 mM sodium molybdate, 1 mM sodium orthovanadate, 
and 5 µg/ml aprotinin] was added at 4ºC.  Lysed cells were scraped from the dish and put 
through three to six cycles of freezing in liquid nitrogen and heating to 100°C for 5 min.  
Samples for Western blots were incubated at 100°C for 5 min with Laemmli sample buffer and 
separated on a 4-15% Criterion gel (Tris-HCl, Bio-Rad Laboratories).  Proteins were transferred 
to PDVF membrane (Pierce Endogen).  Membranes were incubated in a blocking reagent [5% 
(w/v) non-fat dry milk, 0.3% Tween-20 in BSA in TBS] for 2 h.  Membranes were then 
incubated for 16 h in antibody dilution buffer (5% BSA, 0.1% Tween-20 in TBS) with the 
following primary antibodies: anti-phosphorylated-ERK (threonine 202/tyrosine 204) 
monoclonal antibody, anti-phosphorylated FAK (serine 910) polyclonal antibody, anti-
phosphorylated AKT (serine 473) monoclonal antibody , anti-phosphorylated p38 monoclonal 
antibody (Cell Signaling Technology, Beverly, MA), anti-phosphorylated FAK (tyrosine 397) 
polyclonal antibody (Biosource International, Camarillo, CA) at dilutions of 1:1000, or Vinculin 
at a dilution of 1:2000 (Santa Cruz Biotechnology, Santa Cruz, CA).  Membranes were washed 
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for 1 h with 6-8 changes of TBS containing 0.1% Tween-20 and incubated with horseradish 
peroxidase-anti-rabbit IgG (1:10,000 dilution; Accurate Chemical and Scientific Co., Westbury, 
NY).  Membranes were then washed and developed using the Super-signal west femto maximum 
sensitivity substrate (Pierce Endogen).  Labeling was detected and quantified using a Versadoc 
imaging system (Bio-Rad Laboratories). 
Wound Healing Assays 
Migratory properties of melanoma cells were analyzed by a standard wound healing 
assay.  Briefly, cells were plated in 12 well plates at a high density and allowed to grow to 
confluence. Cells were washed 3 times in DMEM/F-12 containing 0.1% BSA, penicillin (100 
U/ml) and streptomycin (100 µg/ml) and then incubated with the same medium for an hour. 
Using a sterile 100 µl tip, a single scratch was made through the middle of each well. The 
medium was subsequently removed and the wells were rinsed three times with DMEM/F-12 
containing 0.1% BSA and penicillin/streptomycin to remove the detached cells. Indicated 
concentrations of cell-surface HSGAG, or recombinant FGF2/VEGF were added to cells in 
triplicates in DMEM/F-12 containing 0.1% BSA, 4mM Hepes, penicillin (100 U/ml), and 
streptomycin (100 µg/ml) for 8 h at 37ºC in a humidified 5% CO2/95% air (v/v) atmosphere.  
Photomicrographs were taken at 0 hour (T0) and at the end of the experiment (T8) using identical 
conditions to calculate percentage of relative gap closure.  Relative gap closure was measured as 
[1-(T8/T0)] for B16B15b.  Migration assays for endothelioma were performed for 18 or 24 h, 
hence relative gap closure for endothelioma experiments were calculated as [1-(T18 or 24/T0)]. 
Proliferation Assays 
Proliferation of melanoma cells was assayed by alamarBlue (BioSource International, 
Camarillo, CA, USA) which monitors the reducing environment of the proliferating cell as per 
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manufacturer’s instructions.  Briefly, 1 x 104 cells/ml were plated into 24 well plates in 
triplicates and incubated and allowed to attach for 24 h.  At the start of the proliferation assay, 
cells were washed 3 times in DMEM/F-12 containing 0.1% BSA and penicillin (100 U/ml) and 
streptomycin (100 µg/ml), and then incubated with the same medium for an hour.  Indicated 
concentrations of cell-surface HSGAG or recombinant VEGF were added to cells in DMEM/F-
12 containing 0.1% BSA, 4 mM Hepes, penicillin (100 U/ml), and streptomycin (100 µg/ml) at 
37ºC in a humidified 5% CO2/95% air (v/v) atmosphere.  For indicated time points alamarBlue 
(10% v/v) was added per well.  Plates were incubated for 4 h at 37°C in a humidified 5% 
CO2/95% air (v/v) atmosphere before spectrophotometric readings were taken.  Cell proliferation 
was measured by monitoring the fluorescence of alamarBlueTM supplemented cell culture media 
at excitation and emission wavelengths of 540 and 630 nm respectively.  The greater is the 
percentage of reduction (fluorescent count), the higher is the proliferative activity.   
In Vivo Angiogenesis Assays 
B16B15b cells were released with PBS-EDTA, washed two times in DMEM/F-12, and 
resuspended at 1x107 cells/ml in 50% reduced-growth factor Matrigel™ (Becton Dickinson, 
Labware, Bedford, MA) in DME/F-12 at 4°C.  HSGAG fragments and VEGF were added 
accordingly.  Cells (2 x 106) were injected using a 25-gauge needle to the left and right 
abdominal subcutaneous tissue of female C57BL6 (Harlan Teklan, Madison, WI) mice (n=6-9).  
Mice were sacrificed on the 10th day.  Tumors were excised, fixed in 10% formalin, and 
embedded in paraffin. Tumor sections (7 µm thick) were then H&E-stained and examined under 
the microscope.  Blood vessel density was assessed by counting all blood vessels within the 
tumor region in five sections in each tumor.  Tumor sections were photographed using an 
Olympus DP70 camera attached to an Olympus BX45 microscope and saved in JPEG format 
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using DP Manager (Olympus America Inc., Center Valley, PA).  Tumor areas were measured by 
counting pixels on ImageJ software (NIH).  Pixel counts were converted to mm2 using a stage 
micrometer to present the number of vessels per unit area.   
Statistical analyses were done using SAS (Version 9.1.3) in an analysis of variance in a 
split-plot arrangement of treatments.  Main plot effects included Group and Animal Id within 
Group; subplot effects included Side and Group*Side interaction.  Pairwise comparisons of main 
effects were conducted with Tukey's HSD test.  When appropriate, interaction effect 
comparisons were performed with t-tests of least-square means.  All comparisons were 
considered significant at p < 0.05.  Prior to analysis, the data were natural log-transformed to 
stabilize variance terms. 
Characterization of Cell-Surface HSGAG  
Isolated B16B15b melanoma cell-surface HSGAG were digested into disaccharides in 20 
mM acetate buffer, pH 7.0, containing 1 µmol of calcium acetate and 5 µg/ml of each of heparin 
lyases I, II and III at 37°C overnight. Digestions were terminated by boiling for 10 min, and 
following centrifugation in an Eppendorf microfuge (10,000 rpm) for 5 min, aliquots were taken 
for direct ion-pair HPLC analysis of variously sulphated ∆-disaccharides.  
Separation of the variously sulphated ∆-disaccharides, isolated by HPSE-degradation 
from melanoma cell-surface followed by degradation with the various heparin- and HS lyases, 
was carried out by ion-pair reversed-phase chromatography (Karamanos, Vanky et al. 1997).  
This chromatography was performed on an Agilent 1100 system (Agilent Technologies Inc., 
Wilmington, DE), using a 4.6 x 150 mm, 5µm I.D. Agilent Zorbax Eclipse XDB-C18 column 
connected to a 7.5x4.6 Altech Altima C18 5 µM guard column.  The flow-rate was 1.25 ml/min 
and the following elution program was used: isocratic elution with 100% A for 8 min, gradient 
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elution to 53.3% B over 26 min, gradient elution to 75% B over 30 min, followed by another 
gradient elution to 100% B over 35 min.  The column was then washed and re-equilibrated by 
further elution with 100% A for 5 min (Karamanos, Vanky et al. 1997).  The absorbance of the 
column elute was monitored at 232 nm (Karamanos, Vanky et al. 1997).  The types of the 
various ∆-disaccharides produced by enzymatic actions of heparin- and HS lyases on HS were 
determined by injecting standard disaccharides, and their compositions were compared to the 
peak heights and/or peak areas obtained with those from external standard disaccharides 
(Karamanos, Vanky et al. 1997).  An internal standard (IP) was used in all samples to control 
technical error (Saad, Ebel et al. 2005).  The linearity of the detector response was tested using 
precisely known amounts of 10 heparin disaccharides (Table 4.1) (Karamanos, Vanky et al. 
1997; Saad, Ebel et al. 2005).  Data were normalized by calculating the ratio of peak area of 
standards to that of internal control IP. 
RESULTS 
Removal and Isolation of Cell-Surface HSGAG with HPSE Treatment 
Highly brain-metastatic B16B15b melanoma cells were chosen as a source of HSGAG 
since they have high expression of HSGAG on the cell surface. The extent of HS degradation by 
HPSE was assessed by detection of cell-surface HS by FACS analysis.  Detectable reduction in 
HSGAG levels was seen with as low as 5 ng/ml HPSE compared to no HPSE treatment (Fig. 
4.1A).  When cells were treated with higher HPSE concentrations (50-5000 ng/ml), a dose-
dependent decrease in cell surface HSGAG was observed (Fig. 4.1A). 
Conditioned medium following HPSE treatment (5µg/ml) from B16B15b melanoma cells 
was collected and HSGAG were isolated by ion-exchange column chromatography (Fig. 4.1B).  
Assessment of HPSE-mediated HSGAG degradation was determined by gel electrophoresis of 
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Table 4.1.  Heparin disaccharide standards 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sugar Nomenclature 
 
 
 
∆UA-2S→GlcNS-6S 
 
I-S 
∆UA→GlcNS-6S 
 
II-S 
∆UA-2S→GlcNS 
 
III-S 
∆UA→GlcNS 
 
IV-S 
∆UA-2S→GlcNAc-6S 
 
I-A 
∆UA→GlcNAc-6S 
 
II-A 
∆UA-2S→GlcNAc 
 
III-A 
∆UA→GlcNAc 
 
IV-A 
∆UA-2S→GlcNCOEt-6S 
 
I-P  (internal std) 
∆UA-2S→GlcN-6S 
 
I-H 
∆UA→GlcN-6S 
 
II-H 
∆UA-2S→GlcN 
 
III-H 
∆UA→GlcN 
 
 
IV-H 
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Figure 4.1.   Dose-dependent reduction of cell surface HSGAG with HPSE.  A. Murine 
B16B15b melanoma cells were treated with 0-5000 ng/ml HPSE.  Cell-surface HS level were 
detected by flowcytometry.  HPSE removes cell-surface HSGAG in a dose-dependent manner, 
(green) 0 ng/ml HPSE, (blue) 5 ng/ml HPSE, (purple) 50 ng/ml HPSE, (light blue) 500 ng/ml 
HPSE or with (orange) 5000 ng/ml HPSE.  Appropriate controls were run to account for 
background staining, (black) no primary antibody control, (solid red) no primary and no 
secondary antibody control.  B. HPSE-degraded cell-surface HSGAG profile on silver stain, 
enzymatic digestions generate smaller fragment that migrate faster on SDS PAGE compared to 
untreated commercial HS.  Various concentrations of untreated HS were run to generate a 
standard curve for determination of concentration of HSGAG after densitometric analysis.  Gel is 
representative of at least three experiments.   
 
 
 
 
 
 
 
 
 109
     A. 
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250 kDa 
 
10 kDa 
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isolated fragments.  Since the isolated HSGAG is a heterogeneous mixture of oligosaccharides 
due to HPSE digestion, it migrates as a broad band during gel electrophoresis (Fig. 4.1B).  
HPSE-mediated HS degradation products migrate faster compared to untreated commercial HS 
indicating a reduction in HS fragment size as expected.  The leading edge of HSGAG profiles 
was determined after densitometric analysis and concentration was determined by generating a 
curve with known standards (Fig. 4.1B). 
Effects of HPSE-Degraded HSGAG on Endothelioma In Vitro 
To study how exogenous addition of HS will influence endothelioma (b.End3) biological 
activity, we added HPSE-digested bovine kidney HS to serum-free endothelioma medium.  HS at 
the concentration range of 0-100 ng/ml did not have any effect on migration (Fig. 4.2A).  We 
also used FGF2, a known mitogenic factor for endothelial cells, at concentrations of 0-100 ng/ml 
(Fig. 4.2B).  At low concentration (1 and 10 ng/ml), FGF2 stimulated migration compared to no 
FGF2 treatment, but at higher concentrations (100 ng/ml), it did not affect endothelioma cell 
migration (Fig. 4.2B). 
To study the underlying signaling mechanisms, we treated b.End3 cells with 1-100 ng/ml 
of FGF2 for 10-30 minutes and analyzed for phosphorylation of ERK (thr 202/tyr 204), AKT 
(ser 473), FAK (tyr 397 and ser 910), and p38 proteins since these molecules are important deter-
minants of tumor survival.  Similar to previous migration study, FGF2 at low concentration 
stimulated phosphorylation of ERK compared to no FGF2 treatment.  At a higher concentration 
(100 ng/ml), FGF2 did not affect phosphorylation of ERK (Fig 4.3A).  Phosphorylation of AKT, 
FAK or p38 were unaffected by FGF2 in endothelioma (Fig 4.3).   
Next, we investigated effects of VEGF at similar concentrations on b.End3.  Unlike 
FGF2 experiments, VEGF was able to stimulate phosphorylation of ERK at 1 ng/ml, but strong  
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Figure 4.2.  Endothelioma migration is not influenced by HPSE-degraded HS but FGF2 
stimulates wound healing.  A. To study how exogenous addition of HS will influence 
endothelioma (b.End3) biological activity, we added HPSE-digested bovine kidney HS to serum-
free endothelioma medium.  HS at the concentration range of 0-100 ng/ml did not have any 
effect on migration.  B. Dose-dependent effect of FGF2 on endothelioma migration (Fig. 4.2B).  
At low concentration (1 and 10 ng/ml), FGF2 stimulated migration compared to no FGF2 
treatment and at higher concentration (100 ng/ml), it did not affect cell migration.  C. Shows 
photographs taken at T0 and T8 hours (melanoma) to explain how the assay works.   
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T = 0 h T = 8 h 
Relative Gap Closure = [1-(T8/T0)] 
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Fgure 4.3.  Phosphorylation of ERK is stimulated by FGF2 and VEGF in endothelioma.  A-
D.  FGF2 at the concentration range of 0 (lane 1), 1 (lane 2), 10 (lane 3) or 100 (lane 4) ng/ml 
stimulates phosphorylation of ERK but not of FAK or p38.  E. VEGF at the same concentration 
range stimulates phosphorylation of ERK.  F.  Vinculin as loading control for E.  G.  Crosstalk 
between various signaling molecules.  Depending on the cellular system, these molecules can 
also act independent of each other. 
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effects were seen at 10 and 100 ng/ml (Fig 4.3E).  Since phospho-ERK is difficult to strip off the 
PVDF membrane; we used the top half of the same membrane to probe for the cytoskeletal-
associated protein vinculin to serve as a loading control (Fig. 4.3F).  Next, we used the 
melanoma cell surface HSGAG isolated by HPSE degradation in the signaling experiments to 
look for changes in phosphorylation of ERK in the presence or absence of 1 ng/ml FGF2 in 
endothelioma.  At low HS concentrations (1-10 ng/ml), FGF2 phosphorylated ERK compared to 
no FGF2 treatment, but HS at a higher concentration (100 ng/ml) decreased this effect (Fig. 4.4). 
We sought to investigate if removal of endothelioma cell surface HS by bacterial 
heparitinase III (Hep III, EC 4.2.2.8) treatment would influence FGF2-mediated endothelioma 
migration and signaling.  We treated the b.End3 cell line with 10 µg/ml of Hep III for 1 h 37oC at 
50 rpm which is the optimum degradation time for Hep III.  Enzymatic removal of cell-surface 
HS by Hep III treatment was incomplete after one hour incubation which was confirmed by flow 
cytometry (Fig 4.5A).  We next treated the cells with heparitinase overnight but, digestion of 
cell-surface HS was still incomplete.  Following treatment, cells were washed three times to 
remove any residual enzyme from the culture plates and the migration and signaling experiments 
were repeated.  Even with partial removal of cell-surface HS, the endothelioma migration 
responded to exogenously added FGF2 (Fig 4.5B and C).  FGF2 influenced the migratory 
behavior (Fig 4.5B) and phosphorylation of ERK (Fig 4.5C) as were already seen in the previous 
experiments.   
We also treated the endothelioma cells with various concentrations of HPSE (0-1000 
ng/ml) overnight to study if HPSE digestion would make any difference in FGF2 or VEGF-
mediated signaling in these cells as were seen with melanoma in our previous study (Reiland,  
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Fgure 4.4.  Phosphorylation of ERK in endothelioma is not influenced by HPSE-degraded 
melanoma cell-surface HS but FGF2 stimulates signaling.  A. To study how exogenous 
addition of HS will influence endothelioma (b.End3) signaling, we added indicated concentration 
of HPSE-digested melanoma cell-surface HS with or without FGF2 (1 ng/ml).  HS at the 
concentration range of 0-10 ng/ml did not have an effect but FGF2 stimulates signaling as 
expected at these concentrations.  However, 100 ng/ml of HS decreased this FGF2-mediated 
effect. 
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 117
 
 
 
 
 
 
 
Figure 4.5.  Enzymatic degradation of cell-surface HS either by Hep III or HPSE does not 
abolish endothelioma migration or signaling.  A. b.End3 cells were treated with Hep III (10 
µg/ml, black) or none (red) for 1 h at 37oC at 50 rpm.  Enzymatic removal of cell-surface HS was 
confirmed by flowcytometry with appropriate controls (blue and green, secondary and tertiary 
antibody control; purple, no antibody control).  Following heparitinase treatment, cells were 
washed three times to remove any residual enzyme from the culture plates and migration (B) as 
well as signaling (C) in response to FGF2 was assayed.  Even with partial removal of cell-
surface HS, FGF2 influenced both the migratory behavior (B) and phosphorylation of ERK (C) 
in the endothelioma as were seen already in the previous experiments.  D.  The endothelioma 
cells were treated with various concentrations of HPSE (ng/ml) (lanes 1-3:0, lanes 4-6:10, lanes 
7-9:100, lanes 10-12:1000) overnight to study if HPSE digestion would make any difference to 
mock (lanes 1,4,7,10) or FGF2 (lanes 2,5,8,11)-/VEGF (lanes 3,6,9,12)-mediated signaling in 
these cells, and again, unlike as seen with melanoma in our previous study (Reiland et al. 2006), 
HPSE treatment did not affect either FGF2 or VEGF-mediated signaling in the endothelioma.   
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Kempf et al. 2006).  HPSE treatment did not abolish either FGF2 or VEGF-mediated 
phosphorylation of ERK in the endothelioma (Fig 4.5D).   
HPSE-Degraded Cell-Surface HSGAG Modify Melanoma Migration 
To directly investigate whether the B16B15b cell-surface HSGAG were biologically 
active, we tested their effects on melanoma cell migration.  The B16B15b cells possess 
aggressive migratory behavior.  When HSGAG were added externally, there was a further 
increase in migration by 30% compared to no treatment (Fig. 4.6A).  Addition of VEGF (0-100 
ng/ml) did not augment this effect compared to control in at least two different experiments.  
Interestingly, VEGF did not influence migration even when added with HSGAG in comparison 
to HSGAG alone (Fig. 4.6A).  This was unexpected since VEGF is known to require HS to exert 
its biological effects.   
We also investigated effects on melanoma migration by adding fibroblast growth factor-2 
(FGF2), platelet derived growth factor (PDGF) and interleukin 8 (IL8) and did not see any 
response.  Interestingly, again we did not see an added effect on migration when FGF2 was 
added to cells with HSGAG in comparison to HSGAG alone (Fig. 4.6B).  As with VEGF, this 
was unanticipated since these growth factors are known to require HS to exert biological effects.   
HPSE-Degraded Cell-Surface HSGAG Do Not Influence Melanoma Proliferation 
We next explored the effect of B16B15b cell-surface HSGAG on melanoma cell 
proliferation to test if similar conditions used in wound healing assays would also affect cell 
proliferation.  Proliferation of melanoma cells was assayed by alamarBlue, a non-toxic dye that 
monitors the reducing environment of the proliferating cell.  Melanoma cell proliferation was 
monitored every 24 h for 72 h.  We did not see an effect on proliferation either by HSGAG or by 
VEGF on melanoma cell proliferation (Fig. 4.7).  Thus, exogenous addition of melanoma cell- 
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Figure 4.6.  HPSE-degraded cell-surface HSGAG modify melanoma migration.  When 
HSGAG were added externally to melanoma cells in wound healing assays, there was increased 
migration compared to control.  Addition of VEGF (A) or FGF2 (B) did not affect migration 
with or without HS. 
 
 122
 
 
 
 
 
 
0
1000
2000
3000
4000
5000
0 20 40 60 80
Time (h)
Fl
u
o
re
sc
en
ce
 
In
te
n
si
ty
 
SFM
HS (HPSE)
VEGF
HS (HPSE) + VEGF
 
Figure 4.7.  HPSE-degraded cell-surface HSGAG do not influence melanoma proliferation.  
Proliferation of melanoma cells were assayed by alamarBlue, a non-toxic dye that monitors the 
reducing environment of the proliferating cell.  Melanoma cell proliferation was monitored every 
24 h for 72 h.  Data are expressed as fluorescence emission intensity units as a function of time 
of incubation.  Exogenous addition of VEGF or melanoma cell-surface HS isolated by HPSE 
treatment did not influence melanoma proliferation in at least three independent experiments. 
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surface HS isolated by HPSE treatment influences melanoma cell migration but does not affect 
cell proliferation.   
HPSE-Degraded Cell-Surface HSGAG Promote Angiogenesis In Vivo 
MatrigelTM plug assay was performed to study the effect of B16B15b cell-surface 
HSGAG on angiogenesis in vivo.  B16B15b cells were resuspended in reduced-growth factor 
MatrigelTM with or without HPSE-degraded melanoma cell-surface HSGAG and injected into the 
right (with VEGF) and left (without VEGF) abdominal subcutaneous tissue of female C57BL6 
mice (n=6-9).  Animals were divided in three groups in a split-plot arrangement.  Group A 
received HPSE-treated HSGAG with (right) or without (left) VEGF.  Group B received HPSE-
treated HSGAG that were further treated with Hep III to cleave them into inactive disaccharide 
fragments with (right) or without (left) VEGF.  Group C received melanoma cells in mock buffer 
with (right) or without (left) VEGF.  Mice were sacrificed on the 10th day post-injection; tumors 
were excised, fixed in 10% formalin, and embedded in paraffin.  Tumor sections (7 µm thick) 
were then H&E-stained to examine for blood vessel formation under the microscope.  Blood 
vessel density was assessed by counting vessels within the tumor region in five different sections 
in each tumor. 
HPSE-treated cell-surface HSGAG induced a significant increase in intra-tumor blood 
vessel formation (Fig 4.8) in animals in group A compared to mock (group C) or Hep III 
treatment of HPSE-treated cell-surface HSGAG (group B) (p < 0.0001).  Interestingly, the 
formation of increased numbers of tumor vessel was VEGF independent.  Presence of VEGF did 
not affect angiogenesis in any of the three groups (p = 0.2-0.8).  Notably, the absence of blood 
vessels inside the tumors led to areas of necrosis because of lack of nutrition and oxygen (Fig 
4.8). 
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Figure 4.8. HPSE-degraded cell-surface HSGAG promote angiogenesis in vivo.  Blood 
vessel density was assessed by counting vessels within the tumor region in five independent 
sections in each tumor.  Tumor sections were photographed using Olympus DP70 camera, 
Olympus BX45 microscope and saved as JEPG format using DP Manager (Olympus).  Tumor 
areas were measured by counting pixels on ImageJ software (NIH).  Pixel counts were converted 
to mm2 to present the number of vessels per unit area.  Statistical analyses were done using SAS 
(Version 9.1.3) in an analysis of variance in a split-plot arrangement of treatments.  A.  
Representative tumor sections from each treatment group (H & E).  HPSE-treated cell-surface 
HSGAG induced a significant increase in intratumor blood vessel (arrow) formation in animals 
compared to mock or HepIII treatment of HPSE-treated cell-surface HSGAG (p<0.0001).  Hep 
III treatment renders the HPSE-degraded fragments inactive, hence abolishes their biological 
activity.  Presence of VEGF did not affect angiogenesis in all three groups (p=0.2-0.8).  Notably, 
inside the tumors, absence of blood vessels, thereby lack of nutrition and oxygen led to areas of 
necrosis.  B.  Bar graph representation of mean blood vessel density with standard deviation 
plotted on a log scale. 
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Structural Analyses of HPSE-Degraded Melanoma Cell-Surface HSGAG  
Isolated B16B15b melanoma cell-surface HSGAG were digested into disaccharides with 
5 µg/ml of each of heparin lyases I, II and III at 37°C overnight.  As a positive control, we used 
bovine kidney HS (50 µg) digested into disaccharides with 5 µg/ml of each of the heparin lyases 
overnight.  Mock digestions were performed on bovine kidney HS in the heparin lyase digestion 
buffer.  Finally, the 5µg/ml of each of heparin lyases in the heparinase digestion buffer was used 
as a negative control.  Heparin disaccharide standards at 0, 10, 20, 40, and 80 µg/ml were run 
before and after the samples to control for variation and method reproducibility (Fig. 4.9A).  
Separation of the variously sulphated ∆-disaccharides was carried out by ion-pair reversed-phase 
chromatography (see methods and materials) (Karamanos, Vanky et al. 1997). 
Disaccharides were recognized in the bovine kidney HS containing sample.  We 
identified disaccharide peaks IVH, IVA, IIA, IIS, and, IIIS in this sample (Fig 4.9B).  The 
heparin lyase non-treated HS did not have any recognizable disaccharide peaks, as expected (Fig. 
4.9C).  We did not identify any disaccharide peaks in the sample containing cell-surface HSGAG 
isolated by HPSE treatment except internal standard IP.  The heparin disaccharide standards 
were identified at concentrations as low as 10 µg/ml.  However, the signal was not very strong.  
Signals for IH and IIIH were low even at concentrations as high as 80 µg/ml (Fig. 4.9D).  
Remaining disaccharide standards generated stronger signals than those of IH and IIIH starting at 
20 µg/ml (Fig. 4.9E).  Hence, the HPLC method we used to characterize the fragments was not 
sensitive enough to generate any signal from the low concentration of cell-surface HSGAG. 
DISCUSSION 
In the present study, we have investigated the role of HPSE-degraded cell-surface 
HSGAG in melanoma tumorigenesis.  Our findings suggest that melanoma cell surface HSGAG 
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Figure 4.9.  Structural analyses of HPSE-degraded melanoma cell-surface HSGAG.  
Separation of the variously sulphated ∆-disaccharides was carried out by ion-pair reversed-phase 
chromatography.  Heparin disaccharide standards at 0, 10, 20, 40, and 80 µg/ml were run before 
and after the samples to control for variation and method reproducibility (A).  Disaccharides 
were recognized in the bovine kidney HS containing sample; we identified disaccharide peaks 
matching standards IVH, IVA, IIA, IIS, and, IIIS in this sample (B).  The heparin lyase-non 
treated HS did not have any recognizable disaccharide peaks (C).  We did not identify any 
disaccharides peaks in the sample containing cell-surface HSGAG isolated by HPSE-treatment, 
data represents at least two different experiments (D).  The heparin disaccharide standards at 
concentration of 80 µg/ml (E). 
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isolated by HPSE treatment promotes melanoma migration and angiogenesis independent of 
VEGF activity.  These results also provide direct evidence that, in addition to remodeling the 
ECM and releasing growth factors and chemokines, HPSE contributes to the aggressive 
phenotype of melanoma by releasing bioactive HS that can possibly stimulate melanoma 
tumorigenesis without the support of any growth factor or chemo/cytokines. 
HSPG (Iozzo 2001) are currently recognized as cell surface/ECM active biological 
modulators (Kjellen and Lindahl 1991), and their degradation at the level of HS chains by 
glycosidases has significant regulatory consequences in cancer metastasis (Liu, Shriver et al. 
2002a; Liu, Shriver et al. 2002b).   Cell-surface/ECM HSGAG are complex polysaccharides that 
are ubiquitous in nature and are characterized by repeating disaccharide units of uronic acid 
(either iduronic acid or glucuronic acid) linked to a glucosamine (Gallagher 2001).  The 
immense structural diversity of HSGAG allows them to bind and interact with numerous proteins 
including growth factors, chemokines, morphogens, and enzymes.  The specificity of growth 
factor binding and interactions is dependent on the HSGAG sequence including their sulfation 
pattern, spacing of binding sites, and the three-dimensional structure of the HSGAG chain 
(Rapraeger 1995; Sasisekharan, Shriver et al. 2002; Robinson, Mulloy et al. 2006).  HSGAG 
present on tumor cells also contain bioactive sequences that may affect tumor-cell phenotype in 
relation to cell growth and metastasis (Sasisekharan, Shriver et al. 2002; Liu, Shriver et al. 
2002a; Roy 2007).  It has been established that growth factor binding to HS, which leads to 
mitogenic activity, takes place only when definite structural features are present within the HS 
chains, such as sulfation at specific positions within a disaccharide (N, 2-O, 3-O, 6-O) by the 
enzymes that mediate HS synthesis within the Golgi (Esko and Selleck 2002).  On the other 
hand, it has also been shown that besides the modification that occurs in the Golgi apparatus 
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during its synthesis and expression, HS can also be structurally and functionally modulated 
within the extracellular compartment.  The two families of mammalian enzymes currently known 
to modify HS are the endosulfatases (Hsulf-1 and -2) that remove 6-O sulfation on the HS (Dai, 
Yang et al. 2005; Narita, Staub et al. 2006) and, HPSE which cleaves HS into small, biologically 
active fragments (Nakajima, Irimura et al. 1983; Nakajima, Irimura et al. 1988; Dempsey, Brunn 
et al. 2000). 
In non-mammalian systems, HS-degradative enzymes, such as bacterial heparitinases, 
heparinases from Flavobacterium heparinum, or endoglucosaminidases, cleave HS to 
disaccharides and tetrasaccharides, which are far  too short for growth factor and ECM ligand 
binding (Ernst, Langer et al. 1995; Ernst, Venkataraman et al. 1996; Liu, Shriver et al. 2002a).  
Conversely, HPSE is a mammalian endo-β-D-glucuronidase that cleaves HS at specific 
intrachain sites, resulting in fragments of appreciable size (10–20 sugar units) (Nakajima, 
Irimura et al. 1984; Nakajima, Irimura et al. 1988; Marchetti 1997; Vlodavsky, Goldshmidt et al. 
2001).  Elevated levels of HPSE are known to be associated with brain-metastatic melanoma 
(Marchetti, Menter et al. 1993; Marchetti, McQuillan et al. 1996; Toyoshima and Nakajima 
1999; Marchetti and Nicolson 2001; Marchetti 2002).  The enzymatic activity of HPSE is 
characterized by specific intrachain HS cleavage of glycosidic bonds with a hydrolase (but not 
eliminase) type of action that facilitates the release of several protein modulators of cell 
functions, including migration, adhesion, inflammation, angiogenesis, embryogenesis, and 
metastatic invasion (Parish, Coombe et al. 1987; Vlodavsky, Bar-Shavit et al. 1991; Hulett, 
Freeman et al. 1999; Kussie, Hulmes et al. 1999; Vlodavsky, Friedmann et al. 1999; Uno, 
Fujiwara et al. 2001; Vlodavsky and Friedmann 2001; Kelly, Miao et al. 2003; Edovitsky, Elkin 
et al. 2004; Reiland, Sanderson et al. 2004; Sasaki, Higashi et al. 2004; Roy, Reiland et al. 2005). 
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When overexpressed, HPSE increases tumor cell invasiveness in vitro and in vivo (Uno, 
Fujiwara et al. 2001; Roy, Reiland et al. 2005); conversely, downregulation of HPSE by anti-
sense or siRNA decreases tumorigenesis both in vitro and in vivo (Uno, Fujiwara et al. 2001; 
Edovitsky, Elkin et al. 2004; Roy, Reiland et al. 2005).  However, at higher concentration HPSE 
can also inhibit tumorigenesis, possibly by extensive remodeling of cell-surface HS that 
interferes with growth factor binding and signaling. In turn, this may lead to subsequent 
inhibition of biological effects (Zetser, Bashenko et al. 2003; Reiland, Kempf et al. 2006). 
Accumulating evidence suggests that cellular function and phenotype are highly 
influenced by the composition and size of HSGAG chains on HSPG (Perrimon and Bernfield 
2000; Liu, Shriver et al. 2002a).  A cell can respond to its microenvironment in markedly 
different ways by dynamically regulating the HS structure on its cell surface as insoluble HS, and 
in the ECM as soluble HS (Liu, Shriver et al. 2002a; Reiland, Kempf et al. 2006).  HSPG and HS 
chains are present on the surface of all eukaryotic cells, including tumor cells and cells that are 
important for tumor survival such as the endothelial cell area surrounding a growing tumor, 
where HS can participate in the process of angiogenesis.  This led us to propose that the pro-
angiogenic activity of HPSE could partly be due to generation of bio-active fragments by its 
enzymatic activity.  We found that these fragments are indeed active and probably mediate their 
effects through melanoma autocrine/paracrine factors. 
Highly brain-metastatic B16B15b melanoma cells were chosen as a source of HSGAG 
since they express large amounts of it on the cell surface. The extent of HS degradation on 
B16B15b by HPSE was assessed by detection of cell-surface HS on FACS analysis.  We were 
able to remove melanoma (B16B15b) cell-surface HS with HPSE treatment in a dose-dependent 
manner (Fig. 4.1A).  Hydrolase action of HPSE introduces a water molecule to the uronic acid-
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glucosamine sequence producing a glucuronic acid at the newly formed reducing terminus.  In 
our cells, the mAb 3G10 epitope recognized the residual cell-surface HS following HPSE 
digestion even though an unsaturated uronic acid of HS is required for 3G10 reactivity (David, 
Bai et al. 1992).  Possibly because 3G10 is an IgM and therefore pentameric, epitope recognition 
may be highly dependent on the organization of HS on the cell surface.  Other groups have also 
detected total HS in nucleus using the 3G10 epitope with strong reactivity (Schubert et al., 2004).  
As expected, the HPSE-degraded cell-surface HSGAG migrated faster than non-treated bovine 
kidney HS (4.1B). 
To directly test whether the B16B15b cell-surface HSGAG were biologically active, we 
tested their effects on melanoma and endothelioma biological activity.  We also reasoned that 
since VEGF is a HS-binding growth factor and is essential for brain metastasis formation (Yano, 
Shinohara et al. 2000), these fragments would participate in VEGF-mediated activities.  VEGF 
also influences a number of pathological conditions that involve abnormal angiogenesis, such as 
rheumatoid arthritis and diabetic retinopathy (Carmeliet 2000).  A single VEGF gene is 
expressed as a number of VEGF isoforms through alternate mRNA splicing that differ by the 
presence or absence of heparin-binding domains (HBDs) encoded by exons 6 and 7 of the VEGF 
gene (Houck, Ferrara et al. 1991; Tischer, Mitchell et al. 1991).  Among the most commonly 
known isoforms, VEGF121 is secreted in the ECM in a free form whereas VEGF189 is 
sequestered in the extracellular matrix (Plouet, Moro et al. 1997).  VEGF165 is the most 
widespread and abundantly expressed splice variant that interacts with HSPG and neuropilins in 
a biologically active form and is found in both secreted and HS-bound form (Plouet, Moro et al. 
1997). 
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Angiogenesis is an important step in solid tumor growth beyond a certain dimension (0.2-
2.0 mm or about 105-106 cells) that requires formation of new blood vessels from the preexisting 
vascular network (Folkman 1971; Folkman, Merler et al. 1971).  Endothelial cells migrate and 
proliferate during angiogenesis and are influenced by the tumor microenvironment including 
heparin/HS-binding growth factors secreted by the tumors such as FGF2 and VEGF (Hanahan 
and Folkman 1996; Iozzo and San Antonio 2001).  Therefore, we decided to study the effects of 
HPSE-degraded HS in an endothelial system.  We first investigated changes in migratory 
properties in murine brain endothelioma cell line b.End3, since migration is a critical event in 
angiogenesis (Carmeliet 2000).  HPSE-degraded bovine kidney HS or cell-surface HS did not 
have any effects on b.End3 endothelioma cell migration or signaling (Fig. 4.2, 4.4), which could 
be due to tissue-specific HS structural differences present between the systems (Esko and 
Lindahl 2001).  Even though the same sets of disaccharides are present in most tissues, their 
relative content varies quantitatively in terms of sulfation or epimerization pattern.  The 
disaccharide sequence GlcA-GlcNS3S occurs predominantly in the endothelial cell system and 
mast cells, and this unit is vital in the pentasaccharide sequence for binding to antithrombin 
(Bourin and Lindahl 1993; Rosenberg, Shworak et al. 1997) while kidney HS contains a large 
amount of IdoA2S-GlcNS3S (Edge and Spiro 1990).  Attempts to remove endothelioma cell-
surface by HS enzymatic degradation of Hep III or HPSE did not alter the response to growth 
factor in this system which could be due to the fact that removal of cell-surface HS was 
incomplete.  Hence, the remaining HSGAG on the cell-surface were enough to mediate growth-
factor mediated signaling (4.5) which is known to occur (Krufka, Guimond et al. 1996). 
VEGF165 binding to VEGFR1 is dependent on cellular HSPG because exogenous 
heparin/HS is unable to compensate for the loss of cell-surface HS, suggesting that HSPG play a 
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role in VEGF165 presentation to cell-surface receptors containing signaling domains (Terman, 
Khandke et al. 1994; Cohen, Gitay-Goren et al. 1995).  VEGF165 is able to bind VEGFR2 in the 
absence of HS, but this interaction is improved by cellular or exogenous heparin/HS  (Terman, 
Khandke et al. 1994; Gitay-Goren, Cohen et al. 1996).  This suggests that HS on the HSPG 
regulates the interaction of VEGF to VEGFR2 and consequent biological activity (Schlessinger, 
Lax et al. 1995).  In our system, however, the presence of VEGF165 did not influence the 
biological activities of the HPSE-degraded melanoma cell-surface HS including migration (Fig. 
4.6) and proliferation (Fig. 4.7) of melanoma in vitro, and angiogenesis in vivo by Matrigel™ 
plug assay (Fig. 4.8).  Carboxylate groups and 2-O-, 6-O-, and N-sulfation of HS promote 
VEGF165 interaction with its receptor; of these sites, 6-O-sulfates appears to be particularly 
important (Robinson, Mulloy et al. 2006).   
A recent report by Robinson et al. 2006 demonstrated that VEGF requires highly sulfated 
sites on the HS for binding.  These sites were exposed by enzymatic action of K5-lyase on HS as 
it demonstrated significant VEGF165 affinity.  In contrast, cleavage of HS by heparinases or 
HPSE severely reduced VEGF165 binding (Robinson, Mulloy et al. 2006).  This may explain the 
reason we failed to observe any biological effect with exogenously added VEGF and HPSE-
degraded HS in melanoma.  Another possibility could be that the basal level of activity that we 
observed was due to either VEGF binding to only endogenous cell-surface HS, or, autocrine 
VEGF produced by the melanoma cells saturated this effect.  However, melanoma cell-surface 
HSGAG were able to stimulate melanoma migration (Fig. 4.5) and angiogenesis (Fig. 4.7) 
compared to the controls, suggesting that these fragments are tumorigenic even if they do not 
affect proliferation of melanoma cells (Fig.4.6).  This finding is further strengthened by the fact 
that, following Hep III digestion, these fragments lose their pro-angiogenic effects. 
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Remodeling of the ECM and BM is vital for normal embryonic development, wound 
healing, and tumorigenesis. During tumor progression, this turnover is highly controlled and 
involves the coordinated action of proteases and endoglycosidases (Sanderson 2005).  This 
process not only contributes to angiogenesis and tumor invasion by altering the integrity of the 
BM/ECM, but also results in the release of HS-binding molecules such as chemokines and pro-
angiogenic growth factors, hence initiating numerous downstream signaling cascades.  While 
large families of proteases (matrix metalloproteases, aspartic, cysteine, and serine proteases) 
mediate the cleavage of protein components of the BM/ECM, cleavage of the HS side chains is 
performed by a limited set of enzymes, including HPSE (Parish, Freeman et al. 2001;  Sanderson 
2005).  Characterization of these HPSE-degraded melanoma cell-surface HS would potentially 
be useful.  Our attempts to do so failed since the method we used did not have high sensitivity to 
low amounts of HSGAG present in the sample (Fig 4.8).  The other methods that are available 
are also mostly optimized to use with large quantities of sample.  Our future plans are to devise a 
method that would isolate individual oligosaccharides which can then be tested for pro-
angiogenic/pro-tumorigenic properties.  Identifying the oligosaccharide HS sequences will also 
lead to characterization of the yet unknown binding motifs for various growth factors such as 
FGF2 and VEGF that interact with HS.  Moreover, the design of novel agents targeted against 
these HS fragments can be an important addition to developing polysaccharide based anti-tumor 
therapy in melanoma. 
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CHAPTER V 
CONCLUDING REMARKS 
 
SUMMARY 
In the first part of these studies it was demonstrated that HPSE is an important molecular 
determinant of metastasis.  Down regulation of HPSE by an adenoviral antisense construct (Ad-
AS/hep) decreased its expression and activity that correlated with invasive cellular properties in 
vitro and in vivo.  Ad-AS/hep treatment of the human brain-metastatic melanoma cells (70W) 
inhibited HPSE-mediated invasion as indicated by the MatrigelTM invasion assay in vitro, and 
decreased lung tumor colonization compared to control in vivo in nude mice (Roy, Reiland et al. 
2005).  When injected in the internal carotid artery, we observed a complete inhibition of brain 
tumor formation following Ad-AS/hep treatment in nude mice.  Unexpectedly, overexpression of 
HPSE by Ad-S/hep also inhibited brain tumor formation possible due to extensive degradation of 
cell surface HS which in turn modifies growth factor activity (Reiland, Kempf et al. 2006).  
Briefly, the results by Reiland et al. (2006), suggested that at low concentration (which mimics 
the physiological concentration of HPSE in vivo), HPSE promotes melanoma tumorigenesis by 
stimulating FGF2-mediated signaling and activity, but at higher concentration it can also inhibit 
metastasis by attenuating FGF2-mediated signaling and activity in melanoma through extensive 
remodeling of the cell-surface HS (Reiland, Kempf et al. 2006). 
Finally, cell-surface heparan sulfate is also known to inhibit or promote tumorigenesis 
depending on size and composition.  We proposed that HPSE generates bioactive HS chains 
from the melanoma cell-surface that modify biological activities associated with vascular 
endothelial growth factor (VEGF), a molecule essential for brain metastasis.  HPSE-degraded 
melanoma cell-surface HS stimulated migration but not proliferation of melanoma in vitro; it 
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also enhanced angiogenesis in vivo, independent of VEGF 165.  This is in agreement with that 
current report by Robinson et al. (2006) which demonstrated that VEGF requires highly sulfated 
sites on the HS for binding and that cleavage of HS by heparinases or HPSE severely reduced 
VEGF165 binding (Robinson, Mulloy et al. 2006).  This may explain the reason we failed to 
observe any biological effect with exogenously added VEGF and HPSE-degraded HS in 
melanoma.  Another possibility could be that the basal level of activity that we observed was due 
to either VEGF binding to only endogenous cell-surface HS, or, autocrine VEGF produced by 
the melanoma cells saturated this effect.  Since, the melanoma cell-surface HSGAG were able to 
stimulate melanoma migration and angiogenesis in comparison to the controls, it indicated that 
these fragments are tumorigenic even if they do not affect proliferation of melanoma cells.  This 
finding is further strengthened by the fact that, following Hep III digestion, these fragments lose 
their pro-angiogenic effects.  Interestingly, HPSE-treated melanoma cell-surface HSGAG did not 
have any effect on endothelioma in vitro.  This could be due to tissue-specific HS structural 
differences present between the systems (Esko and Lindahl 2001). 
We also attempted to characterize the melanoma cell-surface HSGAG isolated by HPSE 
degradation by ion-pair high pressure liquid chromatography.  However, the method was not 
sensitive enough to detect nanogram quantities present in our samples.   
Overall, these results suggested that HPSE is an important molecular determinant of 
melanoma metastasis, and that in addition to remodeling the ECM and releasing growth factors 
and chemokines from the cell-surface, HPSE contributes to the aggressive phenotype of 
melanoma by releasing bioactive HS from the melanoma cell-surface that can stimulate 
melanoma migration and angiogenesis. 
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CURRENT AND FUTURE RESEARCH CHALLENGES 
While considerable progress has been made during the last three decades in 
understanding HPSE biology, there is much more to be learned.  Regulation of the enzyme is 
very tightly controlled under physiological conditions (Parish, Freeman et al. 2001).  There is 
convincing evidence that shows that the enzyme is upregulated in primary and metastatic human 
tumors and this correlates inversely with poor survival rate of cancer patients (Parish, Freeman et 
al. 2001; Vlodavsky and Friedmann 2001).  However, how this enzyme is de-regulated in pre-
cancerous lesions or in cancer is not fully understood.  The exact mechanism by which it 
facilitates tumor progression is also not known.  Despite the fact that its pro-angiogenic property 
is the most accepted mechanism behind HPSE-mediated tumor progression, this requires further 
confirmation.  In the brain-metastatic melanoma as well as a glioma model, overexpression of 
HPSE protein led to inhibition of tumorigenesis suggesting a more complicated role of HPSE in 
the metastatic cascade.  Interestingly, selective expression of nuclear HPSE in breast and 
esophageal carcinoma leads to cell differentiation indicating that nuclear HPSE expression could 
be used as a prognostic marker (Nobuhisa, Naomoto et al. 2007; Ohkawa, Naomoto et al. 2004).  
A few studies have revealed some of the mechanisms that induce HPSE protein expression 
during pathological conditions, but HPSE regulation at the transcriptional, translational and post-
translational levels requires further investigation.   
Additionally, development of a sensitive, high throughput activity assay or ELISA 
method to scrutinize HPSE levels and activity in body fluids of patients is needed in order to 
monitor response to therapy or to predict prognosis.  It has been demonstrated that elevated 
levels of HPSE are detected in the plasma and/or urine of cancer patients as well as in other 
pathological disorders such as diabetes (Katz, Van-Dijk et al. 2002; Levidiotis, Freeman et al. 
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2004).  HPSE is further involved in autoimmune disorders, diabetic nephropathy, and 
inflammatory disorders (Lider, Baharav et al. 1989; Levidiotis, Freeman et al. 2005; Edovitsky, 
Lerner et al. 2006) and we need to investigate the underlying mechanisms.  HPSE is also 
implicated in neuro-degenerative diseases such as Alzheimer’s disease (Bame, Danda et al. 
1997).  HPSE knock-out mice would be useful in this respect and are being generated by several 
groups to gain further insight into the mechanisms responsible in these normal and pathological 
processes.  We also need a clear understanding of the 3D structure of the enzyme to develop and 
screen efficient inhibitory molecules.  Currently, only a single active HPSE enzyme is known to 
be expressed by mammals, but recently a 55 kDa HPSE splice variant has been characterized that 
lacks enzymatic activity (Nasser, Avivi et al. 2007).  The non-enzymatic functions of HPSE also 
point to new areas of interest, including identification of a putative HPSE receptor (Ilan, Elkin et 
al. 2006). 
While HPSE itself is an attractive target for therapy, our lab and others have provided 
evidence that cell-surface HSGAG are bioactive and thus are another attractive target for therapy 
(Sasisekharan, Shriver et al. 2002; Liu, Shriver et al. 2002a).  However, a major barrier to 
devising the HSGAG-related therapy had been the inability to sequence these molecules until 
recently (Karamanos, Vanky et al. 1997; Turnbull, Hopwood et al. 1999; Venkataraman, Shriver 
et al. 1999; Vives RR 1999; Liu, Shriver et al. 2002b; Saad, Ebel et al. 2005).  The slow progress 
in sequencing technology was due to several reasons.  There were very few tools including 
methods to purify the highly anionic HSGAG sequences, as well as few enzymes and chemical 
methods to cleave HSGAG precisely.  Also, unlike DNA and proteins, there is no in vitro system 
available for amplifying HSGAG sequences of interest.  All the available tools to sequence 
complex polysaccharides involve digestion of the HSGAG with bacterial heparitinases that 
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produce di- or tetra-saccharides.  HPSE, however, produces oligosaccharides and therefore a 
method is needed to characterize the mixture of HPSE-digested oligosaccharides.  Once the 
HPSE-generated fragments are isolated and sequenced, the individual fragments can be tested for 
biological activity.  Fragments with the highest metastatic properties can be used to design 
inhibitory strategies which could be effective therapeutically.  Furthermore, identifying the 
oligosaccharide HS sequences will also lead to characterization of the yet unknown binding 
motifs for various growth factors that interact with HS.  Moreover, the design of unique agents 
targeted against these HS fragments can be an important addition to developing polysaccharide 
based anti-tumor therapy in melanoma. 
FINAL COMMENTS 
HPSE has essential pro-angiogenic and pro-metastatic roles, as well as important normal 
physiological functions such as neo-vascularization, inflammation, autoimmunity, and 
embryonic implantation attributed to its enzymatic activity (Ilan, Elkin et al. 2006).  HPSE 
functions by degrading cell-surface and ECM HS and by releasing HS-bound angiogenic growth 
factors (i.e., FGF2, VEGF) from the ECM (Folkman, Klagsbrun et al. 1988) that facilitate 
proliferation, migration, invasion and metastasis (Ilan, Elkin et al. 2006).  Furthermore, HPSE 
degraded bio-active HS fragments can stimulate angiogenesis by modifying activities of 
angiogenic growth factors (Reiland, Kempf et al. 2006).  HPSE activity correlates with the 
metastatic potential of tumor cells; i.e., sub-lines with higher metastatic potential exhibit a higher 
enzymatic activity than low- or non-metastatic cells (Hulett, Freeman et al. 1999; Vlodavsky, 
Friedmann et al. 1999; Yang, MacLeod et al. 2005).  Overexpression of HPSE by transfection or 
an adenoviral gene delivery method increases invasive and metastatic properties in cancers of 
esophagus, lung and in melanoma (Uno, Fujiwara et al. 2001; Roy, Reiland et al. 2005).  
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Conversely antisense, siRNA and ribozyme technologies-mediated reduction of HPSE 
expression leads to a decrease in invasive properties in vitro and in vivo (Uno, Fujiwara et al. 
2001; Edovitsky, Elkin et al. 2004; Roy, Reiland et al. 2005).  Interestingly, exceedingly elevated 
HPSE expression levels can also inhibit tumorigenesis, probably due to extensive cell-surface 
remodeling (Zetser, Bashenko et al. 2003; Reiland, Kempf et al. 2006).  Additionally, selective 
expression of nuclear HPSE in breast and esophageal carcinoma leads to cell differentiation 
which could be used as a prognostic marker in cancer patients (Nobuhisa, Naomoto et al.2007; 
Ohkawa, Naomoto et al. 2004).   
HPSE also exerts non-enzymatic activities, independent of its involvement in ECM 
degradation and remodeling.  Inactive HPSE expressed on the cell-surface leads to firm cell 
adhesion, indicating an involvement in cell–ECM interaction (Goldshmidt, Zcharia et al. 2003).  
Inactive HPSE also enhances endothelial cell migration and invasion (Gingis-Velitski, Zetser et 
al. 2004).   
While we are only starting to appreciate that cells dynamically regulate their HSGAG to 
alter intracellular signaling pathways in highly specific ways, new technologies that have already 
been developed to analyze and synthesize complex polysaccharides are unveiling the importance 
of glycobiology in cancer pathogenesis (Sasisekharan, Shriver et al. 2002).  A better 
understanding of the structure–function relationships of these HSGAGs will help understand 
how they control various aspects of cancer.  ‘Glycoprofiling’ or mapping out cell-surface 
HSGAGs on cancer cells possibly could lead to development of prognostic tools and diagnostic 
screens for cancer detection and staging.  Identifying the HSGAG profile of a tumor might also 
predict its growth and metastatic potential, along with the tumors likely response to therapy 
(Sasisekharan, Shriver et al. 2002).  Finally, the design of novel agents targeted against these HS 
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fragments could be a new cancer therapy.  These molecules also might potentially escape 
immune surveillance in the patients and thus have a long-term therapeutic effect.   
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